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Continuous manufacturing is widely used for the production of commodity products. Currently, it is
attracting increasing interest from the pharmaceutical industry and regulatory agencies as a means to pro-
vide a consistent supply of medicines. Crystallisation is a key operation in the isolation of the majority of
pharmaceuticals and has been demonstrated in a continuous manner on a number of compounds using a
range of processing technologies and scales. Whilst basic design principles for crystallisations and continu-
ous processes are known, applying these in the context of rapid pharmaceutical process development with
the associated constraints of speed to market and limited material availability is challenging. A systematic
approach for continuous crystallisation process design is required to avoid the risk that decisions made on
one aspect of the process conspire to make a later development step or steps, either for crystallisation or
another unit operation, more difficult. In response to this industry challenge, an innovative system-wide ap-
proach to decision making has been developed to support rapid, systematic, and efficient continuous
seeded cooling crystallisation process design. For continuous crystallisation, the goal is to develop and op-
erate a robust, consistent process with tight control of particle attributes. Here, an innovative system-based
workflow is presented that addresses this challenge. The aim, methodology, key decisions and output at
each at stage are defined and a case study is presented demonstrating the successful application of the
workflow for the rapid design of processes to produce kilo quantities of product with distinct, specified at-
tributes suited to the pharmaceutical development environment. This work concludes with a vision for fu-
ture applications of workflows in continuous manufacturing development to achieve rapid performance
based design of pharmaceuticals.
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Design, System, Application
The design and operation of crystallisation processes is a complex subject when considering the range of phenomena such as nucleation, breakage/
attrition, fouling, agglomeration, etc., that can occur in addition to crystal growth. This task is further complicated by limitations on process development
time and material quantities. Here we present a systematic, rapid and efficient workflow approach to the design and operation of continuous
crystallisation of active pharmaceutical ingredients (APIs). To achieve this the workflow contains: clearly described tasks, appropriate use of automation,
minimisation of material usage and resource through experimental design approaches, estimated task time scales and pre-empting of common issues.
Through this approach data driven decisions are made considering their system wide implication, allowing for API particles of specified attributes to be
manufactured by first intent. This standardised approach provides the first steps towards pathways for predictive design of API manufacturing processes.
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1. Introduction
Crystallisation is a complex, multi-phase unit operation used in
a wide range of manufacturing industries to achieve separation
and purification of products.1,2 For the pharmaceutical indus-
try, active pharmaceutical ingredient (API) crystallisation may
be regarded as the first step in the formulation process with
molecules stabilised within the crystal lattice throughout the
subsequent processing steps until the crystal dissolves upon ad-
ministration to the patient allowing the molecular form of the
drug to be absorbed. As a consequence, crystallisation is a criti-
cal process step. The pharmaceutical industry is also placing in-
creasing demands on crystallisation, for example, as drug struc-
tures become more complex they can be more challenging to
crystallise; also, advanced formulations require tighter control
of API particle attributes.3 Industry requires controlled
crystallisations that consistently deliver appropriate chemical
and solid phase purity coupled with a crystal size distribution
and habit suitable for isolation and downstream processing.
These multiple objectives must be met whilst attaining the
highest possible yield at the lowest economic and environmen-
tal cost. The value of the global pharmaceutical industry ex-
ceeds one trillion dollars per year4 and the cost of drug sub-
stance manufacture represents around 150 billion dollars based
on a cost of goods of 20–25%5 and the cost of drug substance
representing around 65% of the cost of goods.6,7 Consequently,
even modest percentage improvements in product consistency,
and/or process yield can lead to significant cost savings.
Crystallisation processes may be classified according to
how supersaturation is generated;8 reactive, evaporative, anti-
solvent and cooling crystallisation can be applied depending
on the nature of the feed stream from the upstream process,
be it a batch or continuous synthesis or workup step. For most
drug substances, the crystal size distribution (CSD) is a critical
quality attribute (CQA) impacting the drug product perfor-
mance in the patient either directly or through its impact in
subsequent processing steps. Consistent achievement of the
required specification for each CQA is a prerequisite of the
material being approved for clinical use. However, multiple
factors including primary and secondary nucleation, growth,
agglomeration, attrition and crystal breakage and encrustation
can all influence the capability of a process to meet a specified
CQA, e.g. particle size. Conventional approaches for obtaining
consistent crystals with CQAs can struggle with batch-to-batch
variability,9,10 particularly at manufacturing scale. In addition,
batch configurations have associated scale-up challenges11,12
when moving from development to production.
Pharmaceutical regulatory agencies are driving the indus-
try to adopt quality-by-design (QbD) methods13,14 to enhance
quality and reduce variability. Process cost reductions and
maximising operation efficiency are key drivers for change
and continuous manufacturing (CM) is widely used to address
these challenges in the production of commodity products.
Recently CM is attracting increasing interest from pharmaceu-
tical industry and regulatory agencies15,16 as a means to pro-
vide a reliable supply of medicines9,17 consistent with QbD.
Continuous crystallisation has been demonstrated on a num-
ber of compounds18–21 using a range of processing technolo-
gies and scales that includes single and multiple stage contin-
uous stirred reactors22–24 and near plug flow reactors, such as
oscillatory baffled crystallisers,25 segmented flow26 and static
mixers.18 In addition to the general benefits of continuous
processing,9,24,27–29 it offers a means to enhance control of
the physical properties of the crystalline product.30,31 Scale-up
or scale-out can also be achieved with less effort and risk.20
Whilst basic design principles for crystallisations and for
continuous processes are known, applying these in the con-
text of a pharmaceutical development programme with the as-
sociated constraints of limited time and material availability
is challenging. This is especially problematic when complex
phenomena such as secondary nucleation, attrition, fouling
or agglomeration significantly complicate the process. These
effects frequently occur and can be highly unpredictable.
Hence, the motivation for this work is to develop a rapid and
efficient means of specifying process parameters, which de-
liver consistent API physical properties, defined by the CQAs,
to optimise both product performance and processability.
Workflows for process development have been reported
and examples are given in Table 1. However, here a novel,
systematic, science-based process design workflow for the ro-
bust design of seeded cooling crystallisation for any API that
identifies process parameters and pre-empts common late-
stage failures modes is developed. Key considerations for the
approach include:
1. Clearly defined experimental and analytical tasks with a
detailed approach to:
a. allow for transparent and systematic data driven decisions.
b. enable facile adaption as the fundamental knowledge
or equipment base develops.
2. Appropriate use of lab automation and automated data
processing to allow:
a. the process developer to focus on the most value adding
steps, e.g. data interpretation and process selection;
b. full exploitation of the advantages of systematic and ac-
curate data recording, archival and retrieval associated with
automated platforms and digital infrastructure such as
electronic laboratory notebooks and machine learning tools.
3. Minimise material usage and resource whilst maximis-
ing process understanding via design of experiment (DoE)
and/or model-based approaches.
4. Allow the realistic estimations of timescales;
5. Pre-empt commonly encountered issues and embed their
solutions to development tasks and decisions.
Here we present the outputs of a large multidisciplinary, in-
dustry demand-led research project that embraces these aspects
to enable a ‘right first time’, science based approach to seeded
cooling crystallisation design. The next section gives a descrip-
tion of the workflow and each of its stages. For each stage the
aim, methodology, key decisions, output and challenges are de-
scribed. Section 3 exemplifies the workflow using paracetamol
(acetaminophen) as a model drug substance. Section 4 discusses
broader applications of the workflow into areas of meta-analysis,
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business case decisions, formulation and drug product design.
Finally, this article concludes with its vision of future applica-
tions of workflows in continuous manufacturing development.
2. Workflow aim and description
Fig. 1 and Table 2 detail the general steps in the workflow de-
veloped here, including the various paths between stages
based on the outcome at specific decision points. This
workflow provides a framework for designing a crystallisation
process but by no means covers all eventualities. It is not
designed to be followed rigorously but instead emphasises a
way of thinking which leads towards holistic process design.
In this workflow, the following assumptions are made:
• Solid-state form predetermined. This workflow does not
address the discovery and identification of different solid-
state forms (polymorphs, solvates, hydrates etc.) but rather fo-
cuses on the production of a predetermined form. Checks are
built into the workflow, particularly during solvent screening
and selection to ensure the desired form is produced.
• Feed composition is constant. Impurities are known to
have a significant impact on crystallisation processes and can
influence the kinetics of nucleation and/or growth, leading to
a change in particle morphology. This workflow assumes that
the level and identity of impurities in the feed are constant
and therefore does not discriminate any effects that changes
in specific impurities may have on the crystallisation process.
Consequently, material used for process development via this
workflow must be consistent in terms of impurity profile and
ideally from a single synthesis lot/batch. Recycling of API is
possible however, checks must be included for increasing
levels of known and new degradation products.
• Initial growth surface managed by seeding. Many methods
are available for the generation of nuclei under supersatura-
tion including, cooling, anti-solvent addition or through ex-
ternal fields, e.g. high shear or ultrasound. Whilst integrated
approaches for manipulation and control of primary nucle-
ation are of considerable interest, they present a significant
challenge for robust, scalable control. Seeding is currently
the industry norm providing a robust method for initiating
crystallisation, controlling solid form and mitigation of fouling.
• Seed generation carried out through an auxiliary workflow.
Assumption 3 dictates the need for seed crystals and it would
be prudent to consider how those seed crystals are generated.
This could be through, for example, wet milling, dry milling,
micronisation or anti-solvent crystallisation. The generation of
this seed material is outwith the scope of the present workflow.
2.1. Stage 1: prior knowledge
Stage 1 of the proposed workflow has three aims. Firstly, it
aims to collate all available information on the compound to
be taken through the workflow. This information can come
from a range of sources, including, but not limited to: molec-
ular design, synthetic route development, solid form screen,
work-up development, previous published literature, analyti-
cal reports, physicochemical molecular properties and struc-
tural features of the API. Pertinent information at this stage
will inform selection of analytical methods, indicate potential
chemical incompatibilities and inform selection or exclusion
Table 1 Example of previous workflow approaches
Workflow Goal
96-Well plates to define a set of scaleable crystallisation conditions32 Conditions to produce 100 g of material
for preclinical testing
High-throughput nanolitre scale workflow33 Crystallisation, imaging, automated storage
and structure determination of proteins
Experimental and modelling aspects of solid–liquid equilibrium,
impurity inclusion, washing and deliquoring34
Managing impurities in crystallisation processes
Preparing the first crystalline solids and solvent screening. Target particle size,
purity, crystallisation vessel, particle morphology, filtration behaviour and scale-up35
Development of new crystallisation processes
Experimental procedures for solubility, nucleation threshold and rate, growth rate
and agglomeration or breakage36
Batch or continuous industrial crystalliser design
Hierarchical procedure covering product and process engineering considering
design specifications, variables and domain knowledge37
Predictive models for solution crystallisations
Multiple dimensional populations, polymorphic transformations and hydrodynamics38 Bottom-up and top-down modelling framework
for batch cooling crystallisations
Estimation for a continuous manufacturing plant flowsheet from which technical
and economic evaluations can be performed39
APIs suitability for continuous processing
Initial screen stage for candidates unsuitable for continuous processing.
Extended evaluation of continuous and hybrid configurations. Execution of
the chosen configuration40
Converting fine chemical processes from batch
to continuous
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of solvents for further investigation in stages 2 and 3. This
may include solid-state landscape, physical form solubility
and relative thermodynamic stabilities, solvate formation pro-
pensity, reactivity and impurity profiles. Data mining of inter-
nal and external databases, such as the Cambridge Structural
Database,41 with structural or relevant process data for re-
lated molecules can also prove useful for prediction of
crystallisation behaviour.42 Secondly, at this stage it is useful
to collate reference characterisation data including XRPD,
FTIR, Raman, DSC, NMR, LC-MS, etc. These will be used
throughout the workflow to ensure the correct form and pu-
rity are achieved. Additionally, melting point or heat of fu-
sion data from DSC can also prove useful for estimating an
API's solubility.43 Finally, this stage sets the product CQAs,
specified by drug product requirements, as the final goal for
the workflow. These CQAs are set by the anticipated dose,
scale of use, dose form and formulation.
2.1.1. Challenges. The key challenge of this stage is that
many of the pre-existing data, detailed above, can be spread
across multiple research or development teams and recorded
using different formats. This can make the data difficult to
search through and retrieve with context. Whilst challenging,
this can be helped through the development of standardised
data acquisition, analysis and reporting approaches through
systems such as electronic lab notebooks (ELN) and digital
data workflows.44 The adoption of good practice concerning
file naming and tagging will ensure experimental measure-
ments are recorded with appropriate context, maximising
their value in enabling subsequent analyses.
2.2. Stage 2: solvent screen and decision 1
This stage is concerned with guiding the selection of a suit-
able solvent for cooling crystallisation (Fig. 1). The aim is
to take a broad library of solvents and rapidly identify only
solvents that show desirable solubility to carry forward into
stage 3. Here, this has been achieved by performing a dis-
solution screen of the compound in solvents from the li-
brary (details in ESI†). The choice of solvents for this
screen can be narrowed by considering the information col-
lated in stage 1 and neglecting any solvents that have
shown any previous indication of an undesired polymorphic
form, solvate formation or reactivity with the solute for ex-
ample. Further restrictions may be placed on the solvent li-
brary to only include solvents listed in the International
Conference on Harmonisation (ICH) classification for resid-
ual solvents45 as class 2 (solvents to be limited) or class 3
(solvents with low toxic potential). Additional restrictions
on the solvent library could include: boiling point, viscosity,
environmental impact46 and cost depending on relevant
project constraints.
Solubility selection criteria were based on the solubility
magnitude and the solubility temperature dependence, both
critical selection parameters for a cooling crystallisation. Spe-
cific solvent selection criteria chosen here are shown in Table 3.
In decision 1 (Fig. 1), if suitable solvents are identified these are
taken to stage 3. However, where no solvents demonstrate a suit-
able temperature dependence, cooling crystallisation in a single
solvent system is unlikely to be feasible.
Fig. 1 Workflow for seeded continuous crystallisation.
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2.3. Stage 3: solvent selection and decision 2
Stage 3 (Fig. 1) is geared towards further narrowing the sol-
vents selected using the selection criteria (Table 4) to inform
selection of one or more candidate solvents to carry forward
to crystallisation assessment in stage 4. Data from these ex-
periments will also be used to extract information concerning
the metastable zone width, agglomeration propensity and
likelihood of fouling. This is done by preparing solutions of
known concentration, C, and subjecting them to temperature
cycles to determine the point of dissolution. Approximate sol-
ubility curves can then be produced by applying suitable fits
(exponential or 2nd order polynomial47) to these points.
From these curves, operating temperature range, yield and
product solid fraction can be estimated to guide selection to
the most appropriate choice. Here yield is defined as the
mass theoretical yield, Yt, calculated from mass solubility
data at initial, T0, and final temperature, Tf:
48,49
(1)
A chemical stability test of the compound in each solvent
at an elevated temperature is also essential here as a further
selection criterion. Similarly, mother liquors from the
crystallisation portion of the temperature cycle should be
analysed by LC, GC or NMR to indicate impurity rejection.
Further considerations to solvent selection can also be incor-
porated here to aid selection, such as health and safety as-
pects and cost. A summary of the selection criteria is shown
in Table 4 with an explanation of their relevance, i.e. which
Table 2 Workflow stage and decision descriptions
Description Output Equipment/tools
Stage 1: prior
knowledge
Collate prior knowledge of API Existing data on API Form screen, synthesis development,
literature, XRD, DSC, NMR
Stage 2: solvent
screen
Assess solubility in a library of process
appropriate solvents
Solvents broadly classified 1.5 mL vials, turbidity
Decision 1 Do any solvents exhibit a temperature dependent solubility?
No: consider alternative isolation method (e.g. anti-solvent crystallisation)
Yes: move solvents with temperature dependence to stage 3
Stage 3: solvent
selection
Detailed solubility measurement and API stability
in solution at elevated temperature
Solvent solubilities and
selection criteria values
5 mL vials, LS-MS, DSC, XRD
Decision 2 Do any solvents meet selection criteria?
No: revisit output of decision 1
Yes: move single solvent to stage 4
Stage 4: PAT selection
and calibration
Assess PAT suitability, calibrate and confirm
solubility
Calibrated PAT method and
detailed solubility curve
100+ mL vessel, UV-Vis, FTIR,
NIR, Raman
Decision 3 Does the PAT calibration meet the required accuracy?
No: revisit PAT selection and calibration
Yes: move to stage 4
Stage 5: system
understanding
Assess relative importance of different processes
(growth, nucleation, agglomeration etc.)
Understanding of API preferred
crystallisation behaviour
Assorted test platforms and PAT
Decision 4 Is the observed crystallisation behaviour compatible with continuous platforms?
No: revisit solvent screen and look at other solvents
Yes: select platform and move to stage 6
Stage 6: process
understanding
DoE and parameter estimation in specific chosen
platform
Model of process 100+ mL vessel, population
balance, DoE, PAT
Decision 5 Is the process model reliable?
No: revisit process understanding and perform further experiments
Yes: design continuous crystallisation and move to stage 7
Stage 7: proof of
concept
crystallisation
Demonstrate continuous operation with design
from decision 5
Desired particle attributes –
solid state, PSD, habit
MSMPR cascade, PFR and PAT
Decision 6 Does the product match the desired particle attributes?
No: revisit process understanding and redesign crystallisation
Yes: workflow complete
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CQAs are influenced by each criteria and which critical pro-
cess parameters (CPPs) control the criteria.
At decision point 2, any solvent that meets all criteria is
carried on to stage 4. However, as with decision 1, if a single
solvent does not meet the criteria set out then the short listed
solvents from stage 2 should be re-evaluated to consider sol-
vent mixtures. Further failure to meet criteria directs that an
alternative crystallisation mode would be preferred, e.g. anti-
solvent or evaporative.
2.3.1. Challenges. A number of challenges exist during
stages 2 and 3:
1. There is often a necessary trade-off between resources
spent and accuracy achieved. In this work, automated plat-
forms for solubility measurement are exploited to minimise ex-
perimental time whilst maximising information obtained. Since
a number of assumptions are made using automated plat-
forms, validation of solubility curves is carried out in stage 4.
2. If solubility of a metastable form is to be investigated,
there are additional challenges to be addressed, such as
preventing form transitions within the time necessary for
measurement.47,50,51
3. As crystallisation is predominantly used as a purifica-
tion technique, the solubility of likely impurities from synthe-
sis would be useful to know to allow for solvent selection
based on impurity rejection. However, it would be time con-
suming to measure solubility for all relevant impurities in all
solvents, see points 1 and 4.
4. Predictive and computational methods could be
exploited at this stage to determine solubility without
performing any experiments. There are a range of methods
currently available, including COSMOtherm,52–54 SAFT,55
UNIQUAC,56 UNIFAC.57 In the context of pharmaceutical
manufacturing, they do not currently provide sufficiently ac-
curate quantitative predictions for a wide range of com-
pounds. However, they are used to give early qualitative rank-
ings of solvent/solute solubility.
5. Selection of a single solvent may prove challenging, as
it has to deliver the desired yield, purity, solid state and mor-
phology of crystals to be accepted. Therefore, a solvent mix-
ture may be required to meet these requirements. Further-
more, the choice of solvent for crystallisation may be limited
without consideration of the crystallisation process during
synthetic route development.
2.4. Stage 4: process analytical technique selection,
calibration and decision 3
The goal of stage 4 is to select appropriate process analytical
techniques (PAT) for the in situ monitoring of the attributes of
interest, including solute concentration, polymorphic form
Table 3 Stage 2 solvent selection criteria
Temperature Solubility
Low temperature threshold 20 °C <50 g L−1
High temperature threshold Solvent boiling point minus 10 °C >50 g L−1
Table 4 Stage 3 solvent selection criteria for a continuous cooling crystallisation process
Parameter CPP CQA Reasoning
Yield, Yt Feed concentration, final
temperature
Yield < 90% likely to be economically unfeasible without recycle. Also
dictates limits on saturated and final T values below
Feed saturated
temperature
Feed concentration Solid state,
purity, PSD
Higher operating T may require specific heat transfer fluids and extensive
lagging to minimise heat loss. Higher T may also accelerate degradation
Final temperature Final temperature Solid state,
purity, PSD
Low final T may require costly refrigerant systems and increase the
complexity of washing and drying during isolation
Product solid
mass fraction
Feed concentration, final
temperature
PSD Solid loadings (at final T) >25 w/w% are a challenge to maintain in a
well-mixed state. Low loadings lead to handling excessive solvent volumes.
Also affects upper boundary of saturated T
Agglomeration Cooling rate, seed loading,
seed size
Purity, PSD Agglomerates complicate growth kinetics and reduce washing and drying
efficiency downstream, potentially lowering purity
Fouling Cooling rate PSD Fouling can prevent the system from reaching steady state, impacts on heat
transfer surfaces, measurement probe windows, CQAs and potentially cause
blockages
Solid state Feed concentration, final
temperature
Solid state Formation of alternative forms is usually undesirable
Particle
shape/crystal
morphology
Feed concentration, final
temperature, cooling rate
Purity, PSD High aspect ratio particles can lead to poor filtration and bulk flow
challenges downstream
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and particle size, during the crystallisation process. In situ
analysis is favoured over off-line approaches as this enables
monitoring and control in real-time, as long as the required
sensitivity and accuracy of the in situ method can be assured.
A range of optical spectroscopic techniques are available for in
situ analysis including UV-visible, NIR, Mid-IR, and Raman.
The different types of measurements available for each tech-
nique along with their key features are given in Table 5. In
some cases, e.g. wide area illumination Raman spectrometry,
techniques can be used to obtain information about both the
liquid (solute concentration) and solid (polymorphic form and
concentration) phases. In comparison, ATR, Mid-IR and UV-
visible measurements can be used to measure selectively the
liquid phase in the presence of particles owing to the short
penetration depth of the evanescent wave. The key purpose of
stage 4 is the selection of a process analytical technique that
can be used for in situ measurement of the solute concentra-
tion. This is required to determine a solubility curve for the
compound of interest in the solvent selected in stage 3 and for
the monitoring and control of the continuous crystallisation
process in subsequent stages (5 to 7) in the workflow.
Measurement of solute concentration requires construc-
tion of a calibration model relating the spectral response to
the dependent variable. For development of a calibration
model that is to be used across a range of temperatures, it is
necessary to either remove the effects of temperature from
the spectra or to include such effects in the model.58 Incorpo-
ration of the spectral variation arising from temperature into
the calibration model can be achieved by subjecting solutions
of different solute concentrations to a stepped heating/
cooling temperature profile, and selection of spectra collected
when the temperature was constant and hence, known. The
model can then be validated using additional spectra col-
lected of solutions of known concentration and temperature
that were not used to build the calibration model. The choice
of calibration model type is dependent on the complexity of
the spectra. For example, if the solute gives rise to a single
peak in the UV-visible region while the solvent does not ab-
sorb, then it may be possible to use a univariate model based
on absorbance or peak area. In comparison, if the solute
spectrum overlaps with that of the solvent, then use of a mul-
tivariate regression model such as partial least squares (PLS)
is likely to be required. Further details of PAT calibration can
be found elsewhere.59–61 The performance of the calibration
model for prediction of solute concentration during a cooling
crystallisation process can also be assessed via an off-line ref-
erence technique such as gravimetry or HPLC.
In summary, stage 4 evaluates the PAT tools required for
the monitoring of the process of interest and the selection
of those that can measure the required attributes with the
required accuracy and precision. In decision 3, if a calibra-
tion model does not meet the required accuracy and preci-
sion during the process, then the calibration model may
need to be re-evaluated after consideration of further pre-
processing options (e.g. removal of the effects of temperature
from the spectra using approaches such as loading space
standardisation62) or another PAT technique (off-line if nec-
essary) considered.
2.4.1. Challenges. 1. Similar to the measurement of solu-
bility discussed above, the accuracy and precision of the mea-
surements is key coupled with efficient approaches to high
quality data collection. Therefore, experiments must be well
designed and implemented to cover the expected operating
window.
2. Selection of a PAT method must be guided by the desired
accuracy of the measurement. A crystallisation system that ex-
hibits a very narrow metastable zone width will require a PAT
method with much higher accuracy and precision to operate
the process in comparison to a system with a much wider zone
width. Precision of in-line or in situ PAT is generally accept-
able, while often lower than that of its off-line counterparts.
3. Whilst it is key to monitor the concentration of solute in
solution during a process, it would also be desirable to moni-
tor the concentration of impurities in situ. However, the con-
centration of impurities is usually below the detection limit of
the optical spectroscopic techniques listed in Table 5 possibly
with the exception of UV-visible spectrometry; although as the
impurities are usually structurally related to the solute, then
measurement of impurities can be difficult owing to spectral
overlap with the much larger solute peak. Therefore, off-line
or on-line UPLC, HPLC or GC may be required.
2.5. Stage 5: system understanding and decision 4
In order to guide development of specific process configura-
tions and crystalliser designs, further understanding of key
crystallisation responses for the selected solute/solvent sys-
tem is required. A summary of these aspects to be assessed is
given in Table 6.
Based on the assessment of these aspects one can develop
understanding of suitable crystalliser configurations:
1. A broad metastable zone width and the requirement for
high supersaturation to trigger secondary nucleation suggests
that the system nucleates slowly. This is desired for a seeded
crystallisation as it increases the design space across which
seeds can be added. There are also practical considerations,
seeding within a narrow metastable zone width (<2 °C) is
likely to be difficult to perform reliably in practice.
2. Secondary nucleation tends to dominate in MSMPR at
elevated supersaturation and quantification of secondary nu-
cleation rate dependence of supersaturation is needed to un-
derstand the dynamics of the crystal size distribution. This
also influences the yield of crystallisation via the surface area
of crystals available for growth. A high secondary nucleation
rate dependence on supersaturation indicates that it will be
difficult to grow large crystals regardless of the equipment.
Adding further vessels to a cascade can help but this may be
offset by increased secondary nucleation associated with
transferring material between vessels.
3. Growth rate at a specific supersaturation dictates resi-
dence time and thus crystalliser volume provided that the sec-
ondary nucleation rate is not significant. For given seed size
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and target product size, seed loading and hence seed feeding
rate can be determined for desired mass throughput.2
4. Depending on the strength of the interparticle forces in-
volved, agglomeration can be reduced through increasing
shear rate levels. For example, if agglomeration propensity is
found to be significant, an MSMPR might be preferred over a
PFR due to the high-localised shear rates in the region close
to the impeller which could break up agglomerates.63 How-
ever, this effect must be balanced with the increase in the
secondary nucleation rate associated with more intense local
shear.
5. Common PFR designs (Table 8) are generally tubular in
nature and have a higher specific surface area in comparison
to MSMPRs. Therefore, if an API was found to have a very
short fouling induction time a PFR should be avoided due to
the increased risk of blockage.
Under ideal seeding conditions (in terms of supersatura-
tion, temperature, agitation) where both primary and second-
ary nucleation are negligible, the number of crystals is con-
served during crystallisation.2 As a result, the crystal mass
deposited through growth is evenly distributed across the
seed crystals. Therefore, design equations that relate
crystallisable mass, seed size and seed mass can be used to
calculate the final crystal size. The mass ratio of seed or seed
loading, Mseed, can be defined by:
73
(2)
Under the assumptions that growth only occurs on the
seeds, a monodispersed seed size and that the number of
seeds is conserved, the product crystal size, Lp, can be related
to the seed crystal size, Ls, by:
2
(3)
where the characteristic size L is a volume equivalent size
(crystal habit being neglected). With the product crystal size
known, assuming that all the crystals have the same shape
and that they grow invariantly at rate G (assumes constant
supersaturation, S). The residence time required to grow
seeds from Ls to Lp can be defined as:
(4)
Eqn (4) gives the time to desupersaturate a solution from
C(T0) to C(Tf). This could be reduced through an increase in
Table 5 Summary of optical spectroscopic techniques for in situ process monitoring
Technique Types of measurements Key features
UV-visible Transmission (weakly absorbing liquids)
and ATR (strongly absorbing liquids)
Molecules must contain a suitable chromophore
Transflectance (liquids and slurries) Can be very sensitive
Reflectance (powders) Compatible with silica fibre optics
Gives rise to broad spectral bands ⇒ multivariate analysis often required
NIR Transmission (liquids) Spectra arise from combinations and overtones of X–H stretching vibrations
Transflectance (liquids and slurries) Not particularly sensitive
Reflectance (powders) Compatible with silica fibre optics
Spectra contain broad, overlapping peaks ⇒ multivariate analysis usually needed
Water absorbs strongly ⇒ good for measurement of low levels of
water but not for analytes present in an aqueous process
MIR ATR (liquids) Good for molecular identification
Can be relatively sensitive
Need to use chalcogenide or silver halide fibre optics
Can be issues with a large background signal from solvents such as water
May be possible to use univariate or multivariate analysis
Raman Reflectance – wide area (solids and slurries) Not particularly sensitive
Reflectance – small area (liquids) Good for molecular identification
Commonly used laser wavelength of 785 nm compatible with silica fibre optics
Water is a poor Raman scatterer ⇒ good for analysis of organics in an
aqueous solvent
Fluorescence can be a major problem
Good for distinguishing between different polymorphic forms
(particularly THz Raman)
May be possible to use univariate or multivariate analysis
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seed surface area (proportional to seed mass, mseed, and in-
versely proportional to seed size, Ls
2). However, consider-
ation must be made not to reduce the desupersaturation
time so far that insufficient time is allowed for the rejec-
tion of impurities at the crystal surface.
To aid in platform selection, Table 7 provides a com-
parison between MSMPR and PFR type crystallisers indicat-
ing which aspects should be considered. Furthermore,
Table 8 describes the different methods of generating plug
flow.
Table 6 Key crystallisation aspects to be evaluated and the product attributes they influence
Key aspect Methodology Rational
Product
attribute
Primary
nucleation
Metastable zone width or induction time Indication of the likelihood of nucleation. For a seeded
crystallisation, the desired state is a wide metastable zone or long
induction time that maximises the window for seed addition
Solid
state,
PSD
Secondary
nucleation
Single crystal or bulk suspension Indication of the supersaturation and agitation required for
substantial numbers of secondary nuclei to be generated
PSD
Fouling Induction time for nucleation on material
surfaces
Presence of undesired nucleation and subsequent growth on surfaces
can cause blockages, prevent the attainment of steady state and affect
heat transfer
Solid
state,
PSD
Growth rate Single crystal growth on hot stage
microscopy or bulk crystal growth through
image analysis
Crystal growth rates dictate the residence time required for crystals to
grow to a target sizea and therefore the volume of the crystalliser
PSD,
purity
Agglomeration Image analysis of crystal suspensions The presence of agglomerates affects PSD, particle shape and
downstream processing such as filtration, washing and drying
PSD,
purity
a In the absence of all other crystallisation processes.
Table 7 Comparisons between MSMPR and PFR configurations
MSMPR PFR
Theoretical yield Lower in a single stage MSMPR where there will be some
residual supersaturation compared to a PFR, especially
where the final portion of the residence time is an
isothermal hold. Introducing additional MSMPR stages can
eliminate this difference
Equivalent to batch in a single pass (assuming sufficient
residence time and equivalent cooling profile)
Design principle Different approach to that of batch. System operates at
fixed points of supersaturation
Relatively easy to convert time in batch to distance along
a plug flow crystalliser
Familiarity/visuals Commonly a single or cascade of stirred vessels. Looks
visually similar to batch
Generally tubular geometry. Visually very different to
batch
Cost of
implementation
Lower cost if converted from existing batch (although
vessel could be overly large). Similar cost to PFR if new
installation
Likely to be high as a new installation. Lab scale can be
inexpensive
Fouling/encrustation Potential of encrusting around liquid levels but unlikely to
block, relatively easy to remove encrustation
Higher likelihood of fouling leading to blockage that is
potentially difficult to remove. Addressed by periodic
pre-emptive cleaning
Cleaning in place For both cases ca. 2 vessel volumes would be required to demonstrate cleanliness
Achievable residence
time
Function of number of stages, volume of each stage and
net flow. Large flexible range. “Lab” scale up to 20 h
Function of length and net flow. Commercial units up to
5 h
Crystallisation
kinetics
Flexible for a range of growth kinetics. Secondary
nucleation can dominate due to impeller/crystal collision
Growth rate at an acceptable supersaturation and
maximum residence time limit the maximum particle
size attainable. Continuous cooling crystallisations in
tubular geometries should always be seeded especially
during start-up to prevent encrustation occurring at high
supersaturations
Crystalliser volume Single stages from 50 mL upwards have been
demonstrated
Lab units exist from 60 mL to 10 L. Commercial units
start at 1.25 L
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Decision 4 (Fig. 1), selection of appropriate crystallisation
platforms requires the measurement of key crystallisation pa-
rameters. These are linked to the characteristics (residence
time, heat transfer, energy dissipation, shear rates, etc.) of
the available crystallisers (Table 7). Using Table 6 and the ex-
planations associated with decision 4, potential
crystallisation platforms can be selected for further investiga-
tion in the workflow. If no crystallisation platform matches
the requirements associated with a particular API/solvent
pairing alternative crystalliser designs may need to be consid-
ered or the solvent selection made in stages 2 and 3 may be
re-evaluated to identify solvents which are more compatible
with the available crystallisation platforms.
2.5.1. Challenges. 1. As these tests support platform selec-
tion, their design and implementation should be as platform
independent as possible whilst simultaneously covering the
range of process conditions expected in the final operating pro-
cess. For example, metastable zone widths are known to vary
with hydrodynamic conditions. Therefore, measurement of
them should be performed in a range of batch platforms that
mimic the conditions found in their continuous counterparts
and the impact of mixing onmetastable zone width assessed.
2. The process developer needs to consider how well results
from small-scale test beds translate to the larger scale continu-
ous environment they are expected to mimic and consider this
when selecting which crystallisation platforms to evaluate.
3. Given the range of measurements required at this stage
a variety of scaled down test beds are of value. Therefore, at
the scales used here, this stage is relatively costly in terms of
both material and time resources.
2.6. Stage 6: process understanding and decision 5
Ideally process understanding should be performed in the
continuous platform selected at the end of stage 5. However,
depending on the specific crystalliser scale, the quantity of
material required to perform this stage in a continuous plat-
form may be prohibitive. If this is the case, then well-
designed batch experiments should be employed which are
in a crystalliser with similar hydrodynamic characteristics as
the chosen continuous platformĲs).
A range of methods can potentially be used at this stage
to develop an understanding of the crystallisation process in
the chosen platform:
1. Design of Experiments (DoE). Commonly used to study
the impact of various process parameters (seed loading, seed
size, etc.) on the product attributes. This is followed by deter-
mination of the design space, which leads to achieving the
desired product attributes. One downside of this approach is
that for full deconvolution (i.e. a full factorial model) of all
the process parameters the number of experiments required
can be significant and impractical. Other DoE models are
available74 which seek to reduce the number of experiments
but can lead to compounding of process parameters.
2. Population balance modelling (PBM). With the estima-
tion of kinetic parameters for the various crystallisation
mechanisms (nucleation, growth, agglomeration) the devel-
opment of a PBM can be possible. Many PBM
implementations have been described and reported75 ranging
from bespoke, freeware formulations implemented in
MATLAB by MathWorks or commercial platforms such as
Table 8 Methods for generating near plug flow
Method Description Advantages Disadvantages Examples
Tanks in series Cascade of stirred vessels with
transfer between stages
Most common Equipment intensive and
reasonable number of tanks needed
(>10)
Paracetamol,64
PABA65
Turbulent
tubular flow
High velocity flow through
tubular section
Simple construction Long lengths required for all but
very fast crystallisations
Benzoic acid,66
glycine67
Narrow bore
laminar flow
Low velocity flow through small
bore (<1 mm)
Simple construction Narrow bore sizes can lead to
blockages
L-Alanine68
Oscillatory flow Pulsations of flow superimposed
on a net flow through periodically
spaced orifices
Reduced length compared to
turbulent tubular flow. Mixing
conditions independent of net
flow
Medium construction complexity.
Oscillations can dampen over long
lengths. Generation of oscillation
can be mechanically complex
Lipoic acid –
nicotinamide,69
salicylic acid,70
L-glutamic acid,69
lactose31
Static mixer
tubes
Typically inserted in tubular
vessels with short alternate
pitched sections which “cut and
dice” the fluid to promote radial
flow
Low to medium construction
complexity. No moving
mechanical components
Readily available in short sections
in a wide range of materials of
construction
Ketoconazole,
flufenamic acid,
L-glutamic acid18
Slug/segmented
flow in tubes
Immiscible fluid added to stream
to separate process into
individual slugs
Low to medium construction
complexity. No moving
mechanical components.
Each slug like a
micro-crystalliser
Can have fouling/blockage issues.
Spontaneous generation of slugs is
within limited operating window
Acetylsalicylic
acid,30 succinic
acid,71 lysozyme72
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gCRYSTAL by Process Systems Enterprise are currently the
most common. Whichever model package is used, carefully
designed experiments are required to achieve reliable estima-
tion of the various parameters.76 Furthermore, model com-
plexity increases as more model mechanisms are required to
describe the process dynamics, for example to describe attri-
tion and/or agglomeration kinetics.
In practice, a combination of both DoE and accurate ex-
perimental kinetic parameter estimation is an effective ap-
proach. Regardless of the approach adopted, the goal is the
same: to develop a model that allows for the identification of
the process parameters required for continuous operation to
deliver product with the desired attributes. In decision 5, the
chosen model should be validated by additional experiments
under conditions that are within the explored design space
but were not used as part of the original model development.
If the model does not predict the validation experiment out-
comes with suitable accuracy, then model development must
be revisited.
In addition to the DoE and PBM methods detailed above,
a third approach employing mechanistic model free control
strategies could also be employed.77 This methodology
would essentially merge stages 6 and 7 and utilise PAT sig-
nals in control loops for process parameters including flow
rate, temperature, concentration, or seed addition rate to
drive the process to the desired product attributes. A limi-
tation of this approach is that it may be difficult to dem-
onstrate understanding of the system behaviour for process
validation, but may be more suitable for complex
crystallisation systems where it could be difficult to make
sufficiently accurate estimations of individual mechanism's
parameters.
2.6.1. Challenges. During model development, the chal-
lenges are often not around the ability to build models, but
the generation of high quality experimental data for parame-
ter estimation:
1. Accuracy of solute concentration measurement. Whilst an
error of 5% in concentration measurement may be accept-
able, how this error propagates through other parameters
needs to be noted. For example, in systems with steep solu-
bility curves the error in measurement of supersaturation will
be much greater in reality.
2. Accuracy of particle size measurement. Samples are typi-
cally taken from the suspension and re-suspended for parti-
cle sizing. Careful method development is required to avoid
inducing any breakage or agglomeration of particles such
that the measured particles are not representative of the orig-
inal sampled suspension.
3. Sampling. It is essential that all sampling methods
employed ensure representative samples are available for
measurement. To partially alleviate this, the PSD is com-
monly measured at the end of a batch crystallisation and the
entire suspension sampled. However, without sampling over
time, valuable information on the PSD trajectory during
crystallisation is lost. Techniques such as focused beam re-
flectance measurement (FBRM) can be used to monitor the
PSD trajectory directly in situ. However, processing of the
chord length data captured is required to convert from the
characteristic chord length to volume density PSD typically
needed for PBMs.78,79
Model building itself is not without its challenges. The
more crystallisation phenomena that occur (secondary nucle-
ation, agglomeration, etc.) the more complex the model be-
comes and more parameters need to be fitted. However, the
addition of extra parameters can lead to over-para-
meterisation. Therefore, aspects of sensitivity analysis are re-
quired to identify which parameters are the most important
to be included.
2.7. Stage 7: proof of concept crystallisation and decision 6
Having developed in stage 6 a model that reliably represents
the crystallisation behaviour of the system taking into ac-
count the process conditions within a specific platform, in
stage 7, the aim is to deploy this model to design a suitable
process to achieve the required product attributes and trans-
late the design into practice. A range of methods for process
design can be utilised depending on the type of model devel-
oped. For example, if the process model was developed purely
through a design of experiments approach then identification
of the continuous process parameters would be via identifica-
tion of the optimal operating region or determination of the
design space boundaries using experimental design software
analysis. This would require setting upper and lower bounds
for the process response (product attribute) values. In con-
trast, if the process model is based on a validated population
balance relying on estimated kinetics then a global optimisa-
tion or Monte Carlo approach can be employed to run a
range of simulations to identify the optimal process condi-
tions. Alternatively, as in stage 6, a combination of popula-
tion balance and DoE methods may also be employed.
Once the desired process conditions have been selected
and the crystallisation platform configuration determined,
the equipment can be assembled in preparation for opera-
tion. The exact details of each configuration will vary
depending on the selected platform (stage 5). However, other
requirements that are common across all platforms are mod-
ules for delivery of a feed solution, delivery of a seed stream
and collection of product. Basic requirements for these mod-
ules include: suitably sized feeding and receiving systems or
vessels for extended continuous operation (or connection to
appropriate upstream and downstream continuous unit oper-
ations), temperature controllers for vessels and pipework and
monitoring and control of mass flow rate. In addition, appro-
priate safety measures such as bunding and head space
inerting must be implemented. For a seeded crystallisation
continuous delivery of a consistent stream of seeds is a criti-
cal requirement. Seeds could be supplied externally by a
stream that is combined with the main feed stream. This
stream consists of seed crystals (ideally non-agglomerated
with a narrow PSD) suspended in saturated solution. The de-
sign of such a supply should consider:
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1. Pipework diameter. Large enough to minimise blockage
but small enough to maintain a high enough velocity to pre-
vent settling/classification. This requirement also applies to
flows in ancillary devices such as mass flow meters.
2. Pump type (if used). The use of pumps can be avoided via
utilisation of pressure transfers.80 However, where pumps are
used the selected pump must be able to transfer particles with-
out causing crystal breakage. Peristaltic or valveless positive
displacements pump are generally suitable for this application.
3. Mixing point design. The point at which the seed stream
meets the main feed stream should be designed such that the
seed crystals are dispersed as quickly and uniformly as possi-
ble into the bulk process volume. This is to ensure particles
do not accumulate at this point and block the seed stream.
Instead of external seeding, seeds can also be generated in
situ. Potential methods include: anti-solvent addition,81 ultra-
sound induced nucleation19,31 and high shear for example as
generated in a rotor stator wet mill.82
A key challenge in constructing an MSMPR cascade is to
ensure controlled transfer of slurry between stages. A range
of possibilities are available, from pump transfer to pneu-
matic transfer under pressure or vacuum. Where pump trans-
fer is used, as with externally seeding by slurry, pump type
and design must be selected to minimise crystal breakage. A
common disadvantage of pumps is that at low flow rates (i.e.
lab scale <20 g min−1) settling of particles and blockages can
occur. This can be partially addressed with periodic trans-
fer.64,83 In this operating mode, pumps operate for a short
period of time at high flow rates to transfer slurry under con-
ditions where particle settling and segregation are
minimised. This requires the use of programmable pumps to
control the desired periodic cycle. An alternative embodiment
of periodic flow is to operate a pump-around loop withdraw-
ing material from the bottom valve of each vessel and
returning it below the liquid surface. In this way, a represen-
tative stream of particles is recirculated. This flow can then
be fed forwards to the next vessel using a timer-actuated ball
valve positioned to allow the transferred material to drain
freely into the next vessel in the cascade.
A further consideration when positioning inlet and outlet
pipes is the minimisation of blockages and the avoidance of
short-circuiting of fluid suspension that would broaden the
product RTD. The inlet pipe can be positioned either sub-
liquid surface or above the liquid surface. Sub-liquid intro-
duction can lead to high local supersaturation although this
can be minimised by locating the end of the pipe in or near
to the impeller zone where the fluid velocity is highest and
mixing fastest. However, blockages can still occur. Position-
ing the pipe end above the liquid surface removes the risk of
high local supersaturation but “bearding” (where a crust
forms around the pipe outlet) is likely to occur. Similar to the
sub-surface introduction the pipe end should be positioned
such that the liquid feed contacts the vessel contents at a po-
sition where it is rapidly mixed with the bulk. For example
with a downwards pumping agitator, this may be close to the
stirrer shaft.
The control strategy84 must also be selected at this point
in crystallisation development. Classical feedback control
strategies (closed loop) such as PID or cascade are suitable
for controlling aspects with simple responses such as temper-
ature or mass flow rate. These relatively straightforward loops
can be used when deploying the lowest level of control to
maintain process set-points. The set-point values are deter-
mined by the process model developed in stage 6. Whilst
such control loops can maintain an operating process this of-
fers no guarantee that the product attributes will not vary.
The availability of real-time process analytical technologies
(PAT) for solute concentration (via ATR-FTIR or ATR-UV) and
particle size and shape (via FBRM or PVM) allow process pa-
rameters that are more directly linked to product attributes
to be included in the process control algorithm. PAT can be
exploited via a mechanistic model or a mechanism free ap-
proach (as mentioned in section 2.6).85 For model-based
strategies the process model interprets the PAT signal and
provides correction of the process parameters (i.e. change in
temperature or mass flow). In contrast, in a model free strat-
egy the PAT signal directly controls a process parameter. Hy-
brid or multi-level strategies are also possible which are com-
posed of aspects from model-based, model-free and closed
loop approaches.
Once a crystallisation process has been designed, operated
and material produced, decision 6 evaluates the extent to
which the product achieved the attributes selected in stage 1,
in addition to product consistency and process robustness. If
neither of these criteria are met, then further process under-
standing is required and the workflow returns to stage 6 to
develop the process model further and redesign/optimise the
crystallisation. If the criteria set for the product and process
are met, then the objective of the workflow is complete.
2.7.1. Challenges. 1. Scale up/technology transfer. Nucle-
ation, growth and agglomeration depend on a range of local
conditions including flow, mixing, supersaturation, tempera-
ture and surface area to volume ratio. As scale increases, rep-
licating heat and mass transfer as well as flow conditions be-
comes more challenging.86 Subject to good control over these
factors, data can successfully be applied when scaling up/
transferring information. The challenge is knowing if the lo-
cal concentration and/or temperature in the scaled up/contin-
uous platform is as expected. Therefore, the ongoing chal-
lenge is the accurate characterisation of continuous
platforms in terms of hydrodynamics, heat and mass trans-
fer. It should also be noted that scale up challenges could be
avoided through scale out/numbering up approaches.27
2. Lack of standardisation. Currently there is no standard
MSMPR design, although partial guidelines do exist,87 and
PFR platforms vary among commercial suppliers. As a result,
implementations of continuous crystallisations can vary be-
tween sites even for the same platform. Consequently,
without documented guidelines learning processes are re-
peated across sites. This also extends to equipment inter-
faces, ancillaries and control systems leading to bespoke
systems.12
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3. Case study: paracetamol
(acetaminophen)
3.1. Materials
Paracetamol (acetaminophen, meets USP specification, 98–
102%) was purchased from Sigma-Aldrich and used without
further purification. All solvents were purchased from either
VWR International or Sigma-Aldrich and while the exact
grade varied between solvents, purity was always > 99.5%
and used without further purification.
3.2. Stage 1: prior knowledge
Paracetamol as a model compound is well characterised and
reported in the literature. For the purpose of this case study
chemical and physical purity of the material as supplied by
Sigma Aldrich was confirmed as paracetamol form I by a
complementary suite of techniques including XRPD (X-ray
powder diffraction), DSC (differential scanning calorimetry)
and NMR (nuclear magnetic resonance). Key data including
crystal structure and reference patterns from each technique
is presented in the ESI.† Solvates of paracetamol have been
reported in 1,4-dixoane88 and pyridine.89 Therefore, these sol-
vents were excluded from the solvent screen as the target
polymorph was the monoclinic form I.
3.3. Stage 2: solvent screen
Solvents used for the screen were restricted to class 2 (sol-
vents to be limited) and 3 (solvents with low toxic potential)
solvents from the ICH classification45 for residual solvents.
Additionally, from the information collated in stage 1, 1,4-di-
oxane and pyridine were removed from the solvent list due to
avoid the risk of solvate formation.88,89
3.3.1. Methodology. 50 mg samples of paracetamol were
weighed into 1.5 mL vials. 1 mL aliquots of each solvent were
transferred by pipette into each vial to achieve concentrations
of 50 g L−1 following the method from Black et al.90 Each vial
was placed in a Crystal16 (Technobis) platform (a 16 vial par-
allel reactor system with monitoring through transmissivity)
and subjected to the following temperature profile:
1. Hold at 20 °C (room temperature) for 1 h
2. Heat to 10 °C below the boiling point of solvent (ele-
vated temperature) at a rate of 5 °C min−1
3. Hold at the elevated temperature for 1 h
Agitation was provided by a 7 mm stirrer bar at 800 rpm
throughout the experiment. At the end of each hold period
the transmission of each vial was recorded. This methodology
was repeated 4 times for each solvent. Based on the transmis-
sion recorded each solvent was classified according to
Table 9.
3.3.2. Results and discussion. Based on the results of the
screen each solvent was placed in one of four classes
(Table 10). Solvents exhibiting low solubility at both room
and elevated temperatures were rejected, as the solubility is
inappropriately low for a cooling crystallisation process. Al-
though it should be noted that they could make suitable can-
didates for anti-solvents. Solvents that returned a high solu-
bility at both temperatures were also rejected on the basis
that the yield from a cooling crystallisation would be too low
and the solubility at a feasible isolation temperature was too
high. Ten solvents that showed a low solubility at room tem-
perature but high solubility at an elevated temperature were
taken to the next stage.
Acetonitrile and nitromethane are ICH class 2, also met
the criteria but were not considered further in stage 3 due to
the additional considerations required for residual solvent
levels during isolation.
3.4. Stage 3: solvent selection
With the initial list of solvents reduced to 8 in stage 2, these
were each studied further to measure their full temperature
dependent solubility curve to inform decision 2.
3.4.1. Materials and method. 150 to 1200 mg samples of
paracetamol were weighed into 8 mL vials. 6 mL aliquots of
each solvent were transferred by pipette into each vial to
achieve concentrations of 25 to 200 g L−1. Each vial was
placed in a Crystalline (Technobis) platform (an 8 vial paral-
lel reactor system with monitoring through transmissivity
and in situ imaging) and subjected to the following tempera-
ture profile whilst monitoring the transmittance of light
through the sample and recording imaging data:
1. Cool to 5 °C (in case dissolution was below ambient
conditions), hold for 1 h
2. Heat to 10 °C below the solvent boiling point (elevated
temperature) at a rate of 0.1 °C min−1, hold at the elevated
temperature for 1 h
3. Cool to 5 °C at a rate of 0.1 °C min−1
Agitation was provided by a 10 mm stirrer bar at 800 rpm
throughout the experiment. The clear point (point of com-
plete dissolution upon heating) was defined as the tempera-
ture during the heating cycle at which the transmission
reached 100% with respect to a sample of the test solvent
measured at ambient temperature. Similarly, the cloud point
(temperature at which crystals are detected upon cooling)
was defined as the temperature during the cooling cycle at
which the transmission deviated from 100%.
3.4.2. Results and discussion. Fig. 2 shows the fitted solu-
bility curves to the data generated using this procedure,
using an equation of the form:
C = a·exp(b·T) (5)
where C is the concentration (g per kg solvent) and T the
temperature (°C). The fitted parameter b, can be used as an
aid to solvent selection by calculating the temperature in-
crease required to double solubility47 via the equation:
ΔTsd = 0.693/b (6)
For the solvents presented in Fig. 2, the solubility was
found to double every 19.3 ± 7.9 °C. This is comparable to
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the qualitative heuristic “Black's rule” which states that solu-
bility generally doubles every 20 °C.90
Building upon the solubility fits, Table 11 provides a sum-
mary of the 8 stage 3 solvents against the solvent selection
criteria previously described in Table 4. For all solvents 5 °C
was chosen as the lower temperature as from a practical per-
spective this allows water to be used as a heat transfer fluid
in the heater/chillers. The saturated temperature was chosen
as the temperature required to achieve >90% yield or the sol-
vent boiling point minus 10 °C, whichever is lowest, whilst
maintaining the product solid mass fraction less than or
equal to 0.25 to enable processability. With these points de-
fined, the theoretical yield operating between these two
points is defined by eqn (1). From the difference between
C(T0) and C(Tf), the mass fraction of solids present in the
product and an estimated throughput for a given solvent flow
rate (50 g min−1) were also calculated (Table 11). Visual
checks were made in each sample for encrustation (fouling)
and oiling out. Other important phenomena associated with
nucleation and growth were assessed based on MSZW and fi-
nal particle size. Growth rates could also be assessed through
image analysis of the in situ particle images with acknowledg-
ment of the limits of an experiment conducted at an 8 mL
scale.
When compared against the selection criteria (Table 4),
butyl acetate, methyl acetate, MIBK, propyl acetate and water
were considered unattractive due to the consistent occur-
rence of crystal agglomeration. Of the 3 remaining solvents,
1-pentanol was excluded from further consideration due to
droplet formation (oiling out) upon cooling. 3-Methyl-1-
butanol was selected in preference to 2-methy-1-propanol on
the basis that 3-methyl-1-butanol delivered a slightly higher
yield (93% vs. 91%) and readily formed large crystals that
would be easier to recover in comparison to 2-methyl-1-
propanol.
3.5. Stage 4: PAT selection and calibration
With the final solvent chosen from stage 3 as 3-methyl-1-
butanol (isoamyl alcohol or isopentanol), an optical spectro-
scopic technique was selected for in situ measurement of sol-
ute concentration. This also enabled the determination of
the solubility-temperature curve for paracetamol in 3-methyl-
1-butanol in the range 0 to 100 °C as well as providing a
means of in situ monitoring and affecting control of the
crystallisation process in stages 5 to 7 of the workflow.
Measurement and control of solute concentration is vital
in crystallisation and techniques that may be influenced by
particle scattering (e.g. Raman backscattering) were not con-
sidered further here. Both UV-visible and IR spectrometries
can be used in conjunction with an ATR probe to measure
the concentration of paracetamol in 3-methyl-1-butanol solu-
tions and suspension. Although 3-methyl-1-butanol absorbs
in the IR but not in the UV-visible region, IR was selected in
Table 10 Classification of solvents based on their solubility classification in stage 2
Room temperature low solubility Room temperature high solubility
Elevated
temperature
low solubility
2-Methoxy-2-methylpropane, anisole, butyl acetate,
chlorobenzene, chloroform, cyclohexane, dichloromethane,
diethyl ether, ethyl acetate, heptane, hexane, isobutylacetate,
o,m,p-xylene, pentane, toluene, trichloroethylene
Elevated
temperature
high solubility
1-pentanol, 2-methyl-1-propanol, 3-methyl-1-butanol,
acetonitrile, butyl acetate, methyl acetate, methyl isobutyl
ketone, nitromethane, propyl acetate, water
1,2-Dimethoxyethane, 1-butanol, 1-propanol, 2-butanol, 2--
butanone, 2-ethoxyethanol, 2-methoxyethanol, 2-propanol,
acetic acid, acetone, DMSO, ethanol, ethylene glycol,
formamide, methanol, N,N-dimethylacetamide, N,N--
dimethylformamide, N-methyl-2-pyrrolidone, tetrahydrofuran
Table 9 Stage 2 solvent screen classifications
Room temperature (R.T.) Elevated temperature (E.T.)
Transmission >95% <95% >95% <95%
Classification R.T. high solubility R.T. low solubility E.T. high solubility E.T. low solubility
Fig. 2 Solubility curves for stage 3 solvents. Water solubility.91
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this case as the software used for spectral acquisition (see be-
low) was fully integrated into the control system simplifying
execution of subsequent workflow stages.
3.5.1. Methodology. All stage 4 experiments were
performed in a Mettler Toledo OptiMax™ workstation of 1 L
capacity, equipped with an in-line Hastelloy® Pt100 tempera-
ture sensor. The system was operated using iControl V5.2
software. For in situ IR experiments a Mettler Toledo
ReactIR™ unit was added to the workstation with iC IR V4.3
incorporated into the iControl software. The spectrometer
was coupled to an ATR probe comprising a diamond crystal
and silver halide fibre optics. An air background was ac-
quired prior to immersion of the probe in the crystallisation
solution. A spectrum was acquired every 15 s comprising 50
scans with a resolution of 8 cm−1. A Mettler Toledo FBRM
probe (G400 series) was used with iC FBRM V4.3 incorpo-
rated in the iControl software and a Mettler Toledo PVM
V819 probe with online image acquisition software V8.3.
For the calibration experiments, a series of fixed concentra-
tions of paracetamol in 3-methyl-1-butanol solvent were pre-
pared at ca. 105 °C and transferred to the OptiMax™ worksta-
tion. A stepped cooling profile, driven by the iControl software,
was completed using 15 °C steps over the range 105 to 0 °C.
Evaporation of solvent at high temperature was minimised by
use of a reflux condenser. Six paracetamol concentrations were
included in the calibration set: 10, 50, 90, 125, 200, 275 g per
kg solvent. Two further experiments were performed to validate
the calibration model: 60 g kg−1 solvent at 20 °C and 180 g per
kg solvent at 65 °C. All experiments were held at a constant
temperature for a period of ca. 30–70 min.
To measure the solubility curve for paracetamol in
3-methyl-1-butanol, a paracetamol–solvent slurry of 300 g per
kg solvent was prepared and a stepped heating profile (5 °C
min−1 ramps and 60 min hold periods) was completed with
excess solids present (confirmed by FBRM total counts)
throughout to ensure a saturated supernatant.
All spectral data were processed using GRAMS V9 software
(Thermo) which was also used to generate the PLS models
via the GramsIQ chemometrics add-on. Only those spectra
that were acquired when the temperature had stabilised were
used to construct the calibration model. All spectra were
baseline corrected and the 1700–800 cm−1 region was se-
lected. Both the spectral and solute concentration data were
mean centred prior to construction of the PLS model. The op-
timum PLS model was selected on the basis of the accuracy
of the predictions obtained for the two validation experi-
ments. The optimum calibration model employed 6 latent
variables and R2 was 0.99966. The calibration model was
then used to determine the solubility curve for paracetamol
in 3-methyl-1-butanol from IR spectra acquired when the tem-
perature was constant during the hold periods.
3.5.2. Results and discussion. The predicted solute con-
centrations in the two validation experiments were 72 and
191 g kg−1 compared to actual concentrations of 60 and 180 g
kg−1, respectively. Although this gives an error of 6 to 20%
(with the larger error present at lower concentrations), thisTa
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was deemed to be adequate for subsequent steps in the
workflow.
The temperature dependent solubility curve obtained for
paracetamol in 3-methyl-1-butanol by in situ IR spectrometry
is shown in Fig. 3. The plot obtained is in reasonable agree-
ment with the data obtained using the Crystalline platform
shown in Fig. 2.
3.6. Stage 5: system understanding
To inform platform selection a series of assessments were
carried out of processes that may impact the performance of
seeded cooling crystallisations (primary and secondary nucle-
ation), alter the resulting particle attributes (agglomeration)
or continuous process performance (fouling). Crystal growth
rates were also quantified to guide the crystallisation process
design, residence time selection and final crystal size
distribution.
3.6.1. Primary nucleation. Primary nucleation was
assessed by measurement of the metastable zone width
(MSZW) in a range of crystallisers. In stage 3 the MSZW at
5 mL scale was assessed as part of the solubility investiga-
tion. In this stage, 1.5 mL (utilising Crystal16 platform as
part of subsequent secondary nucleation assessment) as well
as three hydrodynamic environments in different small scale
batch platforms were carried out to enable efficient assess-
ment of factors impacting the process. Specifically:
1. 1 L stirred tank reactor (Mettler Toledo OptiMax™
workstation), equipped with a Hastelloy® Pt100 temperature
sensor. Agitation was provided by a 45° pitched blade turbine
rotating at 350 rpm.
2. Moving fluid oscillatory baffled crystalliser (MF-OBC)92
of 125 mL capacity, equipped with a PTFE coated Pt100 tem-
perature sensor. Tube diameter was 15 mm with a baffle ori-
fice diameter of 7 mm and baffle spacing = 22 mm. Oscilla-
tion was provided by a 25 mm diameter PEEK piston using
frequency and amplitude of 1.5 Hz and 20 mm, respectively.
3. Moving baffle oscillatory baffled crystalliser (MB-OBC)92
of 120 mL capacity, equipped with a PTFE coated Pt100 tem-
perature sensor. Vessel diameter was 24 mm with baffles
23 mm in diameter fitted with a single 10 mm orifice and
spaced 37 mm apart. Baffles were connected via stainless
steel 316 L support rods. Oscillation of the baffle string was
at 1.5 Hz and 20 mm amplitude.
The operating conditions for the scale up crystallisers
were selected to maintain similar mixing intensities corre-
sponding to a volume average energy dissipation rate of
0.160 W kg−1 (based on the minimum suspended speed for
the expected particle size in the Optimax crystalliser). This
was achieved through control of stirrer rotation rate in the
stirred tank and oscillation frequency and amplitude in the
MF-OBC and MB-OBC crystallisers.
For Crystal16 MSZW assessment, sample compositions
of 100, 117, 130 and 148 g per kg solvent of paracetamol
in 1 mL of 3-methyl-1-butanol were used. 1.5 mL glass vials
were tightly sealed with a lid and para-film to avoid solvent
evaporation and placed in the Crystal16. The heating and
cooling rates between 10 °C to 80 °C were set to 0.5 °C
min−1. Samples were stirred with a controlled stirring
speed of 700 rpm, using a PTFE coated magnetic stirring
bar.
A FBRM probe with iC FBRM V4.3 was used in each
crystalliser configuration to track nucleation. Five fixed con-
centrations of paracetamol in 3-methyl-1-butanol; 50, 80, 120,
160, 200 g per kg solvent were prepared and heated to 85 °C,
then held for 1 h to ensure complete dissolution. Cooling
was then applied at 1 or 0.16 °C min−1 (0.16 °C min−1 repre-
sents the slowest linear cooling rate achievable in the avail-
able crystallisation platforms useable in stage 7). The nucle-
ation temperature was taken as the temperature at which the
number of FBRM particle counts in the sub 10 μm range
exceeded 100 per s. Comparison of the average MSZW over
the five concentrations measured in these crystallisers along
with Crystal16 and Crystalline experiments in stage 3 are
shown in Table 12. The temperatures at which nucleation
was observed under the selected conditions are shown in
Fig. 9. Across all crystallisers, the narrowest MSZW was ob-
served in the MB-OBC for concentrations <120 g per kg sol-
vent and in the 1.5 mL stirred vessels at concentrations
>120 g per kg solvent. Taking a conservative approach using
the narrowest MSZWs, Fig. 9 shows the primary nucleation
threshold, .
3.6.2. Secondary nucleation. Stirred vessels were used to
assess the secondary nucleation behaviour at a convenient
crystalliser volume of 3 mL. A temperature calibration was
performed to achieve accurate solution temperature. Non-
invasive in situ imaging using a camera with a resolution
of 2.8 μm per pixel and a depth of field of 2.5 mm was
used to monitor experiments. The camera allows particles
to be counted from sequential images. Since the volume
in which the particles are counted is not exactly known,
the obtained secondary nucleation rate is in arbitrary
units.
Fig. 3 Temperature dependent solubility profile of paracetamol in
3-methyl-1-butanol.
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Four stock solutions with various concentrations were pre-
pared. Complete dissolution was verified by heating the sam-
ples to 20 °C above the saturation temperatures whilst stir-
ring at 500 rpm on a stirrer hot plate. Each stock solution
was quickly filtered to minimise the amount of heteroge-
neous particles or residual seed present and transferred into
a pre-warmed bottle. The warm, filtered stock solutions were
then divided into 3 mL vials through a pre-warmed syringe. A
magnetic stirrer bar was added to each vial and the vials were
tightly closed with a lid before they were located in the Crys-
talline workstation at a stirrer speed of 700 rpm. At each
supersaturation a seeded and unseeded experiment (serving
as controls) was carried out.
8 vials were placed inside the instrument per run and so-
lutions heated to 20 °C above their saturation temperatures
and maintained at these temperatures for 20 min to ensure
complete dissolution prior to cooling. At the highest tempera-
ture the solutions were undersaturated and a cooling profile
of 5 °C min−1 was applied generating each target supersatura-
tion ratio. The solutions were prepared with compositions
such that the required supersaturation ratio (S = 1.9, 2.0, 2.1
and 2.2) was attained at a target temperature T = 20 °C.
Vials were removed from the instrument once the solu-
tions reached the desired temperature. One vial was seeded
with a single crystal of form I paracetamol. The second vial
was not seeded with any crystal but in every other respect, it
received the same treatment as the seeded sample. The vials
were replaced in the Crystalline platform which was taken as
t0. Time tn indicates the time from which primary nucleation
can be expected to occur. Based on the MSZW values,
Table 12 Comparison of MSZW in a range of crystalliser configurations
Cooling
rate
Average metastable zone width (°C)
1 °C min−1 0.5 °C min−1 0.16 °C min−1 0.10 °C min−1
Crystal16 — 32.1 ± 4.1 — —
Crystalline — — — 28.8 ± 20.6
Optimax 28.7 ± 0.8 — 20.9 ± 6.9 —
MF-OBC 28.6 ± 18.1 — 19.9 ± 2.4 —
MB-OBC 18.5 ± 8.1 — 22.9 ± 14.6 —
Fig. 4 a) Particle count, N, in arbitrary units against time for seeded
secondary nucleation experiments at different supersaturation ratios.
b) Observed secondary nucleation rate, B, in arbitrary units as a
function of the supersaturation in the seeded experiments.
Fig. 5 Sequential fouling images for a) borosilicate (0, 205 and 602
min) and b) Hastelloy® C276 (0, 107 and 653 min) at S = 2.00.
Fig. 6 Typical a) microscopy images of single crystal growth and b)
crystal face lengths as a function of time for initial S = 1.25 at 50 °C.
Fig. 7 Example growth rates from Crystalline PSD.
Molecular Systems Design & EngineeringPaper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
0 
Fe
br
ua
ry
 2
01
8.
 D
ow
nl
oa
de
d 
on
 8
/1
/2
01
8 
11
:5
8:
06
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Mol. Syst. Des. Eng., 2018, 3, 518–549 | 535This journal is © The Royal Society of Chemistry 2018
sufficiently low supersaturations were chosen to prevent pri-
mary nucleation occurring. This allowed enough time after
the desired temperature was reached to seed the supersatu-
rated clear solution. This was also checked by performing a
parallel unseeded experiment to each single crystal seeded
test. Therefore, effects caused by primary and secondary nu-
cleation can be distinguished.
Fig. 4a shows the results for seeded experiments at differ-
ent supersaturation ratios. For the secondary nucleation rate
measurements, a threshold of 10 particles was used to define
the delay time before secondary nucleation occurs. When the
count per frame reached over 200 particles, the particle count
is not reliable because the particle suspension is too dense
and it is not possible to identify single particles reliably.
From the slope of the fitted lines in Fig. 4a, the secondary
nucleation rate, B, in arbitrary units can be obtained and is
shown as a function of supersaturation in Fig. 4b. The mea-
sured secondary nucleation increases with supersaturation:
for S = 2.2 secondary nucleation is 3 times faster than that at
S = 1.9. Extrapolating a linear fit to these supersaturation de-
pendent secondary nucleation rates allows the determination
of a supersaturation threshold, = 1.79, at which the sec-
ondary nucleation rate, B, is zero. As the supersaturation re-
quired for primary nucleation changes with solubility, the
secondary nucleation supersaturation threshold would also
be expected to change. To estimate this, the ratio between
the primary, secondary nucleation thresholds and solubility
was defined as:
(7)
Using the values for (2.17) and (1.78) at 20 °C, RB
was found to be 0.667. A rearrangement of eqn (7) was then
used to calculate over the full working temperature range
in Fig. 9.
3.6.3. Fouling. A fouling platform based upon an adapta-
tion of a commercial corrosion testing platform (Zebrafish,
Cambridge Reactor Design) was used to investigate the vul-
nerability of different materials of construction (MOC) to
fouling as a function of crystallisation process parameters.
The fouling platform consists of a heating/cooling unit that
contains a sample of the solution under investigation and a
peristaltic pump (313 Drivsure, Watson-Marlow) to provide
continuous flow of solution through the flow cell which recy-
cles into a holding vessel. The custom made flow cell can
hold different MOC coupons such that the solution flow is di-
rected towards the coupon face. A temperature controlled
stream of water was directed at the rear of the MOC coupon
from a Julabo F25 unit via a miniCORI-FLOW™ (Bronkhorst)
mass flow controller in order to cool the MOC surface to in-
duce fouling. The Pt100 sensor in the crystallising solution
entering the flow cell dictates the heating/cooling of the hold-
ing vessel to reach and maintain a specified temperature.
The bespoke flow cell includes four Pt100 temperature sen-
sors, which determine temperature differences between
crystallising solution entering and leaving the cell and the
heat transfer fluid stream entering and leaving the cell over
time.
Paracetamol and 3-methyl-1-butanol stock solutions were
prepared (66.5 g per kg solvent) which corresponds to a satu-
ration temperature of 40 °C. This was heated until fully
dissolved and 250 mL of the resulting solution was added to
the circulation vessel. The solution was circulated around the
fouling platform at 40 °C i.e. undersaturated. Once tempera-
ture determined by all of the Pt100 sensors had stabilised at
a constant value, the circulating heat transfer fluid was
Fig. 8 a) Example PVM images for S = 1.50 at 400 rpm experiment and
b) trends of particle convexity distribution mode. Agglomerating
reference represents the trend for a strongly agglomerating system
(acetone95).
Fig. 9 Operating space in the phase: cloud points (Crystal16,
Crystalline, Optimax, MF-OBC and MB-OBC platforms), secondary nu-
cleation experiments and corresponding threshold, fouling experi-
ments and corresponding threshold, growth and agglomeration exper-
imental conditions.
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cooled. Local supersaturation was generated on the
crystallisation solution side of the material coupon by cooling
the heat transfer side. It is assumed coolant entry tempera-
ture is identical to the local surface temperature of the mate-
rial coupon. Once the cold stream was initiated it was as-
sumed that supersaturation at the MOC coupon was
constant. Images were recorded every 30 s using a mono-
chrome camera and IC capture software. Solution and cool-
ant flow rates were both kept at 50 mL min−1 throughout all
experiments, as was the circulating solution temperature at
40 °C. Local supersaturations (dictated by the coolant tem-
peratures of 26.4, 20.7 and 15.9 °C) investigated were S =
1.50, 1.75 and 2.00, respectively, for both Hastelloy® C276
and borosilicate glass. Fouling induction times and example
images collected are shown in Table 13 and Fig. 5,
respectively.
From the results in Table 13, the fouling threshold can be
defined as S = 1.75 for Hastelloy® C276. Assuming this con-
stant S across the operating temperature range the fouling
threshold is shown in Fig. 9. It can be seen that the fouling
threshold intersects the conservative primary nucleation
threshold at 30 °C. This is unsurprising given the close rela-
tionship been fouling induction time and MSZW.93 There-
fore, for temperatures >30 °C it was assumed that the fouling
threshold was equal to the primary nucleation threshold.
3.6.4. Single crystal growth. With thresholds for primary
nucleation, secondary nucleation and fouling defined
(Fig. 9), conditions under which only growth would be
expected can be selected. 4 conditions covering this potential
range were chosen for the measurement of growth rates
(Fig. 9 and Table 14).
Solutions of paracetamol in 3-methyl-1-butanol were pre-
pared which had the desired relative superstation, S, at each
target temperature (Table 14). These solutions were
maintained at 20 °C above the saturation temperature for 1 h
to ensure complete dissolution. A single crystal was placed in
the slide well of a Linkam (LTS420) microscopy hot stage and
held at the desired crystal growth temperature leading up to
the experiment. This was done to ensure the single crystal
and Linkam stage were at the desired temperature from the
start of the experiment. Prior to the experiment, a 1 mL sy-
ringe with 0.1 μm filter was kept in an incubator <5 °C above
the desired temperature. This was done to minimise the im-
pact of momentary cooling when transferring the supersatu-
rated solution to the microscope hot stage. Once the stage
and syringe were at the desired temperatures, the solution
was quickly cooled to the target temperature and the solution
transferred into the slide well. This contained the thermally
equilibrated test crystal. Imaging commenced immediately
after the supersaturated solution was added. When a com-
plete sequence of images had been collected, the crystal
growth rate was determined by manually measuring the crys-
tal dimensions in successive images in the sequence of
frames. Typical crystal face measurements and their change
with time are shown in Fig. 6. The range of crystal face
growth rates observed are summarised in Table 16.
3.6.5. Bulk crystal growth. During solubility determination
(stage 3), in situ images of particles were recorded. These im-
ages were analysed via the instrument software to generate
PSDs based on the circle equivalent diameter of the identi-
fied particles. Raw PSD data from the images (number
weighted) was used to produce a volume weighted distribu-
tion, assuming spherical particles, and the dv75 calculated
(dv75 values were chosen as these would be less influenced
by the formation of new particles through any nucleation
events). Values for dv75 over time for a range of paracetamol
solution concentrations and initial supersaturations are
shown in Fig. 7. Growth rates were determined from the gra-
dient of a fitted linear trend. The range of bulk crystal growth
rates observed are summarised in Table 16.
3.6.6. Agglomeration. In order to qualitatively assess and
make a semi quantitative measurement of the degree of ag-
glomeration a modified version of the image analysis ap-
proach detailed previously94 was adopted. 100 mL solutions
of paracetamol in 3-methyl-1-butanol saturated at 40 °C
(66.5 g per kg solvent) were prepared in a stirred vessel
(Easymax workstation), equipped with FBRM and PVM
probes. Solutions were heated to 50 °C and held for 1 h to en-
sure complete dissolution. The solutions were then cooled to
the target temperatures (Table 15) using conditions that
would avoid nucleation. At the target temperature, 1 g of
paracetamol seed crystals were introduced. Seeds were
suspended into 5 mL of room temperature saturated solution
followed by 30 s of ultrasound to disperse the seed crystals
before charging into the vessel. Solutions were then held iso-
thermally for 2 h. Images recorded by the PVM probe were
analysed for any indication of agglomeration through moni-
toring changes in particle convexity94 via an in house image
analysis algorithm. Fig. 8a shows examples of PVM images
collected at S = 1.50 with 400 rpm stirring over the first 15
min after seed addition. The trend of the mode of the parti-
cle convexity distribution is also shown (Fig. 8b). In compari-
son to a strongly agglomerating system (e.g. paracetamol in
Table 13 Fouling induction times for material of construction and local
supersaturation
Local
supersaturation
Fouling induction time (min)
Hastelloy® C276 Borosilicate
1.50 No fouling after 12
hours
No fouling after 12
hours
1.75 278 No fouling after 12
hours
2.00 107 No fouling after 12
hours
Table 14 Experimental conditions for single crystal growth experiments
Crystal growth temperature (°C) Relative supersaturation, S
25 1.05
25 1.25
50 1.05
50 1.25
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acetone95) it can be seen that the particle convexity shows
only minimal change. This confirms that the shape of the
crystals did not change and indicates that no agglomeration
occurred. No evidence of agglomeration was observed over
the range of experimental conditions investigated. It can be
concluded that the propensity of paracetamol to agglomerate
in 3-methyl-1-butanol is negligible.
3.6.7. Platform selection. Table 16 summarises the results
of the experiments described above. Fig. 9 displays the pri-
mary nucleation, secondary nucleation and fouling thresh-
olds relative to the solubility, growth and agglomeration ex-
periments. This also highlights the operating region in which
a crystallisation would be desired to operate in to achieve a
process dominated by growth. Based on these results the fol-
lowing conclusions on the crystallisation of paracetamol in
3-methyl-1-butanol were drawn:
1. Nucleation kinetics are slow. Both primary and second-
ary nucleation kinetic measures indicate a high level of super-
saturation is required for the formation of new particles.
2. Fouling poses little risk at moderate supersaturations.
3. Growth rates are in such a range that they could be eas-
ily controlled by S.
4. Agglomeration propensity is low.
As stated in section 2.5 none of these statements rule out
a specific crystallisation platform. For example:
1. Metastable zone widths are suitably wide to allow for
seeding in all platforms.
2. Fouling poses little risk therefore a PFR could be used
with minimum risk of blockage, assuming operation at ap-
propriate levels of supersaturation.
3. Agglomeration was not observed therefore specific levels
of shear above that for uniform mixing and particle suspen-
sion are not required to disperse agglomerates.
4. Growth rates would require residence times and
crystalliser volumes that are compatible with the available
laboratory scale PFR and MSMPR systems.
Hence for the case of paracetamol in 3-methyl-1-butonal,
crystallisation in a wide range of platforms, covering MSMPR
and PFR, would be possible. For the demonstration purposes
of this case study an MSMPR cascade platform was chosen as
the focus for the later stages of the workflow.
Estimation of the required platform volume is required to
ensure suitable equipment selection and configuration. As-
suming the slowest bulk crystal growth rate of 2.26 μm
min−1, a net flow rate of 12.5 mL min−1 (lowest of available
pumps) using eqn (2) to (4) the product size, required resi-
dence time and crystalliser volume were estimated, as a func-
tion of seed loading and seed size (Table 17). The
crystallisation process design is refined as part of stage 6
once an appropriate model has been developed.
3.7. Stage 6: process understanding
The aim of stage 6 was to estimate kinetic parameters for use
in a population balance model, which will be used in subse-
quent stages to identify suitable operating conditions.
3.7.1. Methodology. All experiments were performed in an
STR (Mettler Toledo OptiMax™ workstation) of 1 L capacity,
as described previously in section 3.5. To estimate the growth
parameters a series of seeded crystallisations were performed
under constant supersaturation control. In order to calibrate
the ReactIR for supersaturation control, 111 g of paracetamol
and 600 g of 3-methyl-1-butanol were charged into the
Optimax vessel. This solution was:
1. Cooled to 5 °C at the fastest possible rate.
2. Held at 5 °C for 2 h to allow for solid/liquid
equilibrium.
3. Heated to 85 °C over a 16 h period.
4. Held for a further 2 h period.
Agitation was fixed at 600 rpm (0.053 W kg−1) supplied by
a 45 mm pitched blade turbine (PBT). This step enables the
IR absorbance of saturated solution as a function of tempera-
tures to be determined and modelled. The solution was then
cooled to 80 °C minus a temperature offset (either 5 or 8 °C
for S = 1.08 and 1.20, respectively, to operate within the
thresholds in Fig. 9). Once this temperature was reached the
required seed mass was charged as dry seed into the vessel
and the supersaturation control was then started using the
absorbance-temperature model. 5 °C was set as the lower
bound for the temperature. Seeds were prepared by sieving of
ball milled commercial paracetamol. Two seed sizes, with
dv50 of 40 and 100 μm, were utilised in addition to two seed
loadings, Mseed, of 0.019 and 0.036. On completion of each
experiment, the contents of the vessel were filtered and the
cake washed twice with 2 cake volumes of chilled diethyl
Table 16 Summary of results from stage 5 system characterisation experiments
Mechanism Measure Result
Primary nucleation Narrowest metastable zone width 18.5 °C
Secondary nucleation Secondary nucleation threshold S = 1.79 at 20 °C
Fouling Fouling threshold S = 1.50
Growth rate Single crystal face 0.79 to 2.42 μm min−1
Bulk crystal 2.26 to 19.97 μm min−1
Agglomeration Particle convexity distribution mode change Negligible
Table 15 Conditions investigated during agglomeration study
Supersaturation, S Seeding temperature (°C) Agitation rate (rpm)
1.05 38.1 250
1.10 36.3 250
1.05 38.1 400
1.10 36.3 400
1.50 24.1 400
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ether. The wet cake was then transferred to a vacuum oven
for drying. Once dry, particle size distributions of the product
were measured by laser diffraction (Malvern Mastersizer
3000) using isooctane as a dispersing fluid (due to its negligi-
ble solubility and wetting properties of paracetamol).
For parameter estimation, a model of the Optimax vessel
was built in gCrystal 4.2.0 using an MSMPR unit operation
configured in batch mode. Time invariant controls for the
model included mass of crystals in slurry, liquid composi-
tion, PSD location parameter and PSD standard deviation.
Temperature profiles were input as piecewise linear controls
by approximating the temperature profile determined by the
supersaturation control to a series of linear segments.
To prevent agglomeration affecting the estimation of
growth parameters, only the concentration profile monitored
by ReactIR, and quantified by the previously developed cali-
bration model (section 3.5), was used as measured data to fit
against. Kinetic parameters were the growth rate constant, kg,
activation energy, EA,g, and order with respect to supersatura-
tion, g, for a power law relationship given by eqn (8) and (9).
It was assumed that no nucleation took place within this
seeded batch experiment.
(8)
(9)
3.7.2. Results and discussion. The predicted concentration
profiles from the two fitting experiments shown in Fig. 10a
were used to estimate the kinetic parameters given in
Table 18. Fig. 10a also highlights that good fits can be
achieved. This is reflected in the weighted residual between
significantly less than the 95% χ2 value in Table 18.
To validate these growth parameters and the mechanistic
assumptions used the model and experimental PSDs of the
product particles were compared for a pair of additional vali-
dation experiments (Fig. 10b). There is generally good agree-
ment between the dv50 results, indicating that the growth pa-
rameters accurately represent the system. However, the
experimental PSDs do show more small particles in the distri-
bution than is predicted. This may be due to attrition, sec-
ondary nucleation or breakage taking place in the process or
that particle breakage is induced by the particle sizing
method. However, these model deviations were judged ac-
ceptable in light of the selected target specification and the
model was sufficiently accurate to inform the remaining
workflow stages. Where required, further investigations to de-
termine additional kinetic parameters could be undertaken
and various approaches have been described.76
3.8. Stage 7: proof of concept crystallisation
To implement the proof of concept crystallisation, consider-
ation must be given to how seed crystals are generated and
introduced to the process. As stated above, this is not the fo-
cus of this study, however a brief outline of the ancillary
workflow used is provided. A rotor stator wet mill (RSWM)
(MagicLab, IKA) was used for the generation of seed crystals
in a recycle configuration based on a single MSMPR stage
(Fig. 11). This method has been described elsewhere.82 De-
tailed description of the characterisation, modelling and pa-
rameter estimation for this unit will be covered in a follow
up publication. The key parameter in this method is that the
temperature of the single MSMPR stage controls the
crystallisable mass and therefore the number of seeds that
can be generated. For ease of operation, this seed generation
unit was integrated with the other MSMPR stages. An inte-
grated flowsheet was also produced in gCrystal 4.2.0 covering
both the seed generation and crystal growth stages.
3.8.1. Process design. Based on the validated kinetic pa-
rameters from stage 6 a range of crystalliser configurations
and conditions can be evaluated computationally. Initial con-
figuration scoping focused on the number of MSMPR stages
required. 1, 2 and 3 stage configurations were considered
and evaluated on the basis of productivity, practical control
and efficiency. A single stage configuration was quickly
discounted as the stage temperature required to maintain
supersaturation below the levels for primary or secondary nu-
cleation would lead to low crystallisation productivity (Fig. 9).
Configurations of 2 stages and greater presented little in-
crease in productivity whilst increasing the configuration and
control complexity. Therefore, a compromise was met with a
Table 17 Estimated product sizes, Lp, required residence times, τ, and
crystalliser volume, V
Mseed
Ls = 10 μm Ls = 20 μm
Lp (μm) τ (min) V (ml) Lp (μm) τ (min) V (ml)
0.2 18 3.6 45 36 7.2 90
0.1 22 5.4 68 44 10.8 135
0.05 28 7.8 97 55 15.6 195
0.01 47 16.2 202 93 32.4 405
0.005 59 21.5 269 117 430 537
Fig. 10 Comparison of experimental and model a) concentration
profiles and b) product particle size distributions.
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2 stage configuration. A range of operating conditions were
then investigated in the model considering the factors of:
stage temperatures, stage volumes and net flow rate. The
product particle size, PSD span, product volume fraction of
crystals (linked to yield) and stage supersaturation were cal-
culated as responses. To minimise the number of simula-
tions, a D-optimal linear experimental design was developed
to investigate the impact of the selected factors on the re-
sponses. This experimental design was selected for its ability
to handle constraints placed on the factors. For example, the
stage temperatures must decrease, i.e. T1 > T2. Examples of
the response curve and design space are shown in Fig. 12.
From the design space probabilities, the configuration to
produce particles with a dv50 of 110 μm, whilst considering
the previously determined constraints on stage supersatura-
tion, was identified as stage volumes of 1500 mL, net flow
rate of 100 g min−1 and stage temperatures of 77.3, 50 and
20 °C, respectively. Operating points of these MSMPR stages
are shown in Fig. 9 to compare against the operating thresh-
old for primary nucleation, secondary nucleation and fouling.
3.8.2. Process implementation. At this stage a range of
control options are available for operating the continuous
process. In this example, local control loops for mass flow rate
and temperature were used to maintain set-points as indi-
cated by the process model developed. Process analytical tools
were used for monitoring but were not used to effect control.
Equipment was configured to deliver the selected condi-
tions (Fig. 11). The equipment consisted of a Microinnova
Engineering GmBH miniflow plant acting as a feed unit
(combining thermostat (Lauda, Proline 855), delivery pump
with feedback control from a Coriolis mass flow meter (Sie-
mens)), three 2 L glass reaction vessels (Radleys) each with a
working volume of 1.5 L, three thermostat circulators (Lauda
420), a rotor stator wet mill (MagicLab, IKA) and two lab filter
dryers (Powder Systems Ltd, Maxi Lab). Process monitoring
was achieved through the mass flow meter, Pt100 probe in
each vessel for temperature control, FBRM probe in all
crystallisation vessels and a ReactIR15 in the 3rd
crystallisation vessel. Continuous material transfer between
crystallisation stages was maintained through application of
positive pressure (N2 at 0.1 bar) to the first stage. Agitation in
all crystallisation stages was provided by retreat curve impel-
lers operated at 600 rpm and aided by three equally spaced
baffles.
Preparation of the plant for start-up consisted of the fol-
lowing stages:
1. 25 L of feed solution was prepared in the feed vessel at
a concentration of 188 g per kg solvent of paracetamol in
3-methyl-1-butanol. This solution was heated to 90 °C and
maintained at this temperature until complete dissolution
had occurred.
2. During this period, trace heating on the pipework and
associated components (in-line filter, pump, mass flow me-
ter) from the feed vessel to the first crystallisation vessel was
commenced with a set point of 100 °C.
3. The crystalliser thermostats for each stage were set to
their required temperatures of; 77.3, 50 and 20 °C,
respectively.
4. Product valve, V-4 was set to recycle back to the feed
vessel.
5. Each vessel was initially empty and un-pressurised.
Table 18 Parameter values as a result of parameter estimation
Model parameter Value Units
Activation energy, EA,g 0 J mol
−1
Growth rate constant, kg 3.64 × 10
−4 m s−1
Order with respect to supersaturation, g 4.127
Weighted residual 2.616
χ2 value (95%) 38.885
Fig. 11 Process and instrumentation diagram of configuration for stage 7.
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Start-up was performed by transferring feed solution at
100 g min−1 (as controlled by mass flow meter and pump)
into the seed generation stage. Once this stage was approxi-
mately 50% full the RSWM was switched on to trigger nucle-
ation. Filling of this vessel continued until the 100% level
(1.5 L) was reached at which point positive pressure was ap-
plied to enable material transfer to crystallisation stages 1
and 2. Once stage 2 reached its maximum level, material was
transferred back to the feed vessel via a 3-way valve (V-4,
Fig. 11). This recycle configuration allowed the cascade to
reach steady state without consuming material. Once a steady
state was achieved, as indicated by the PAT instruments
showing minimum variance for 2 residence times, V-4 was
turned to start product collection in the pair of pressure filter
driers operating in duty and stand-by mode. Filtration was
performed once 10 L of product suspension was collected.
The filter cake was washed three times with two cake vol-
umes of diethyl ether with agitation between washes to maxi-
mise removal of 3-methyl-1-butanol. Drying was performed
under vacuum at 40 °C for 3 h. Diethyl ether was selected as
a wash solvent based on the low solubility of paracetamol
(stage 2 screen), miscibility with 3-methyl-1-butanol and low
boiling point. A total of 3 continuous campaigns were
performed to produce 6.5 kg of paracetamol over 6 filtration
lots.
Fig. 13 shows the process trends collected from FBRM
during one of the continuous campaigns. This highlights the
dynamics of the start-up process showing steady state was
not obtained until approximately 350 min. Optimisation of
start-up conditions to minimise time to steady state was not
in the scope of the current study. Operation in recycle contin-
ued until 440 min to ensure steady state operation was
achieved. Once steady state was obtained and the process op-
erated in single pass mode, the process trends remain rela-
tively constant for the remaining 250 min of operation (the
time taken to deplete the feed vessel). With a total mean resi-
dence time (across all three crystallisers) of approximately 45
min this would indicate a requirement to operate for 6 to 7
residence times before steady state was achieved. This is
comparable to the generally accepted 7 to 10 residence times
required for MSMPRs to reach steady state.96 From the FBRM
measurements in Fig. 13, there is an increase of approxi-
mately 20 μm in the median size between stages 1 and 2 at
steady state. In addition, Fig. 13b also shows the chord
length distribution for the seeds generated.
Fig. 14 shows the results of particle size and shape analy-
sis (measured by Malvern Instruments Morphologi G3) for
the six filtration lots (A–F). In particular, Fig. 14a highlights
the variation of PSD across the filtration lots in comparison
to the average across all lots and the model predicted PSD
from stage 6 of the workflow. Average dv50 for the lots was
found to be 112.0 μm with a standard deviation of 16.2 μm.
Similarly, the average span of the distributions was 1.66 with
a standard deviation of 0.18. In comparison to the model pre-
dicted target size of a dv50 of 110 μm with a span of 1.53 it is
concluded that the modelling framework was sufficient to ac-
curately represent the process conditions and that the pro-
cess configuration was operated to closely match the ideal
conditions identified by the model. Fig. 14b gives the particle
shape distributions relating to the elongation and circularity
of the particles. These are features that are not captured by
the 1-dimensional population balance model used to predict
the process. As with the PSDs it can be seen that there is little
variation across the filtration lots with median elongation
and circularity values of 0.298 ± 0.013 and 0.849 ± 0.013, re-
spectively. The values of both these measures suggest that
particles are of low aspect ratio shape with low surface rough-
ness. This is reflected in sample particles shown in Fig. 14c.
It should be noted that the lot PSDs and average PSD is
broader than that of the model predicted PSD. This could be
for a number of reasons including:
1. Unaccounted for crystallisation mechanism(s). As the ex-
perimental PSDs are broader in both directions this would in-
dicated that both attrition and agglomeration may need to be
accounted for. These mechanisms could be present in the
crystalliser itself or could be induced during filtration and
drying or occur during the PSD measurement method. A fur-
ther explanation is that there could be a dispersion of growth
rates within the crystallisation. Further investigation into
these mechanisms would be merited where tighter control of
the PSD is warranted.
2. Broader residence time distribution. The model assumed
ideal uniform mixing throughout the process. However,
Fig. 12 Example a) response curve and b) design space showing
probability of failure for a 110 μm product size.
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despite the MSMPR being baffled to ensure it was as well
mixed it is conceivable that product removal between vessels
was not representative leading to a broader residence time
distribution. As a result, particles would experience a wider
range of growth times leading to a broader PSD.
In addition to the particle size analysis, additional tests
were performed to give an indication of the product lots' per-
formance in downstream unit operations. This included mea-
surement of the product powder bulk and tapped density de-
termined according to USP 616 Method I (Autotap,
Quantachrome Instruments). The Hausner ratio was calcu-
lated according to USP 1174 and is shown in Fig. 15. Values
ranging from 1.14 to 1.21 indicated that the product lots'
flow character ranges from good to fair.
3.9. Summary
Through the application of a systematic workflow for the de-
sign of a seeded paracetamol crystallisation process, this case
study has demonstrated the selection of a suitable
crystallisation solvent (3-methyl-1-butanol) which achieves a
high yield whilst maintaining the desired solid form and
minimising issues such as agglomeration or fouling. Suitable
PAT was also identified to monitor the crystallisation process
with appropriate accuracy (on-line FTIR-ATR). An array of
testbeds was used to study crystallisation behaviour across a
range of crystallisation platforms. MSMPR and PFR
crystallisers were identified as suitable. An MSMPR platform
was selected as an example for this case study. Based on this
platform a mechanistic model capturing the crystal growth
kinetics was developed. Utilising this model a range of pro-
cess configurations were investigated covering; number of
stages, stage volume, stage temperature and net flow rate. An
integrated crystalliser configuration consisting of a RSWM
with MSMPR for seed generation and 2 stage MSMPR with a
mean residence time of 45 min was selected as suitable for
the production of particles with a dv50 of 110 μm. Finally,
based on this proposed configuration a proof of concept
crystallisation was performed operating at the set points
pinpointed. This proof of concept covered three continuous
campaigns over 12.5 h leading to the production of 6.5 kg of
paracetamol with a dv50 of 112 ± 16 μm. Furthermore, char-
acterisation of the product lots revealed that the product par-
ticles showed good to fair flow character.
This methodology was also deployed to produce an addi-
tional 2 size bands of paracetamol (dv50s of 50 and 70 μm,
respectively) in the same solvent system but in different pro-
cess configurations, details of these will follow in subsequent
publications.
4. Applications of a workflow
4.1. Meta-analysis/machine learning
With an increasing emphasis placed on efficiency, control
and mechanistic understanding, model-based tools are see-
ing greater utility in pharmaceutical manufacturing.97–99 In
Fig. 14 Comparison of product lot a) particle size distributions, b)
particle elongation and circularity distributions and c) sample particle
images.
Fig. 13 a) Example process trends from proof of concept crystallisation
and b) chord length distributions across each MSMPR stage.
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the context of continuous crystallisation, a wealth of in-line
and off-line data sources exist which can potentially be used
to construct models. A key use of machine learning models
here, given the constraints on time and materials, would be
to predict experimental outcomes, reducing the number of
experiments that must be carried out in the laboratory. How-
ever, machine learning approaches require at least a modest-
sized dataset for training before they can make accurate pre-
dictions. Since experimental outcomes in this area tend to be
highly dependent on many precise operating parameters
used, a pre-existing and exactly matching dataset is often
unavailable. The implementation of a systematic workflow
creates powerful new opportunities for data mining and
meta-analysis of experimental results. With access to consis-
tent, fully contextualised data from multiple APIs across all
workflow stages, it becomes possible to explore inter-
experimental relationships.
For the case study described, limited meta-analytical work
could be demonstrated since experimental data points were
only generated for paracetamol. However, a simple example
is presented to illustrate the current capabilities and limita-
tions of predictive modelling when working without pre-
existing experimental data. MSZW data for each solvent
short-listed at stage 3 were chosen, since this kinetic mea-
surement is highly sensitive to experimental conditions.100,101
A binary response was created of the data: “yes” for data
points where a metastable zone was detected over the course
of the experiment (regardless of width) and “no” for those
where no metastable zone was detected. For each solvent,
molecular descriptors were calculated using MOE.102 Descrip-
tors were then filtered for correlation with a threshold of 0.6
before separating the data into training and testing sets. A to-
tal of 52 data points were available (several concentrations
per solvent): 28 were assigned to the training set and the rest
to the testing set, maintaining an even spread of data points
per solvent and data points per concentration across both
sets.
The randomForest package within R103 was used to train a
random forest (RF) model. For information on the RF
method, the reader is referred to a selection of
publications.104–106 The model was then used to predict the
detection of a metastable zone in test set experiments,
achieving 91.7% accuracy (22 of 24 cases correct). Fig. 16
shows a multi-dimensional scaling (MDS) plot of the test set's
proximities. In brief, this is a spatial representation of how
often cases received the same classification in the model. Ide-
ally, all cases of each class would be highly proximal,
appearing in tight clusters (one per class) in MDS space. Even
with a small dataset, this RF model performed well; this is
because the question it provided predictions for was tailored
around the available data. It was necessarily a highly specific
question, namely whether a metastable zone will be detected
for a given concentration of paracetamol under the precise
experimental conditions used throughout. Changes to any ex-
perimental parameters, including the identity of the solute,
would be out of the model's scope, requiring it to be
retrained with a different dataset. This limited the utility of
the model to intra-experimental predictions, i.e. further data
points beyond the 28 that had to be found experimentally.
The above scenario is prevalent in the context of continu-
ous crystallisation: while great quantities of experimental
data are generated, they often cannot be combined and
repurposed to construct models due to the vast number of
varying parameters associated with them. Following a consis-
tent, well-defined workflow lays the foundations necessary
for the collection of systematic, comparable experimental
data. Each successive compound progressing through it aug-
ments the knowledge base, enabling the mining of data
points from previous workflow iterations and the construc-
tion of cross-API models (cf. the above example model
constrained to only a single API). A source of reliable and
consistent data, facilitated by a systematic workflow, is an es-
sential platform towards the ultimate goal of predictive
crystallisability versus manufacturability.
4.2. Future supply chain design
The emergence of both new technologies and therapy areas
has the potential for dramatically changing the pharmaceuti-
cal manufacturing and supply chain landscape.107,108 One
key research area involves the design of more agile continu-
ous processing based supply chains, in order to manage fu-
ture demand requirements of increased product complexity,
more product variety, shorter product lifecycles, and smaller
drug volumes.109
This section summarises how a crystallisation workflow
may be utilised to inform the design of future pharmaceuti-
cal supply chains. The workflow serves as an important asset
in the development of a standardised data acquisition, analy-
sis and reporting system, and may help identify emerging
patterns and clusters of drug products that may benefit from
similar supply chain design and reconfiguration opportuni-
ties in the future (in better understanding the design space,
accelerating and de-risking development, and reducing
costs). In conjunction with a supply chain analytical
Fig. 15 Comparison of Hausner ratio of product lots.
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framework previously reported,108 recent studies have shown
network design activities integrating outputs from the
crystallisation workflow to evaluate potential benefits and op-
portunities for case-specific integrated end-to-end supply
chain scenarios.107 The integrated process is summarised in
Fig. 17.
4.2.1. An integrated workflow – supply chain analytical
framework. In addition to collating available information on
the candidate compound as part of crystallisation workflow
stage 1 – prior knowledge (e.g. synthesis route development,
solid form screen, and work-up development), supply chain
criteria can be used to identify barriers to adopting alterna-
tive product-process technologies and business models.108 In
summary, this involves exploring future trends (where imple-
mentation of continuous technologies may have a cost advan-
tage or increased speed to market) and market requirements
(in terms of volume and product variety, affordability and
unmet needs). Basic operational and societal data include:
Therapy or disease area; Patient population; Treatment profile;
Volumes (current, projected); Basic financials (price, cost, reve-
nues, margin); Stock-Keeping Units (SKU) mix; Inventory;
CapEx; Quality/waste. This ‘pre-screening’ step can inform
crystallisation workflow activities around future state product
particle attributes and drug product requirements, as well as
facilitate the rapid analysis (‘go’ vs. ‘no-go’) of whether an
existing candidate compound or new molecule may be a via-
ble candidate to investigate further in terms of business case
evaluation.
In addition to informing workflow activities, process and
network designers are using outputs from stage 1 of the
crystallisation workflow for rapid product assessment and
continuous process selection. In addition to yield, quality,
form, purity, and consistency, ten critical ‘attributes’ – in
terms of technology feasibility and chemistry are considered
at this pre-screening step,107 with a focus on complexity and
area(s) of opportunity in the context of ‘continuous’
processing:
• Molecule
• Polymorph
• Chirality
• Number of process steps
• Particle engineering
• Kinetics
• Stability
• Bioavailability
• Final dosage form
• Ease of scale-up/scale-out
Crystallisation workflow outputs also inform the mapping
of the ‘current state’, in terms of technologies, unit opera-
tions and the supply chain. The first current state mapping
exercise identifies those unit operations where an existing
batch production process may be ‘pre-disposed’ to a series of
continuous technologies (in terms of current state and future
potential), namely, in synthesis; purification; isolation; formu-
lation and packaging. While evidence exists that continuous
processing delivers financial benefits for single-purpose
plants, a business case for transformation assessing the re-
sultant impact across the end-to-end (E2E) supply chain is
needed for such a technology to be better quantified, and for
the upstream and downstream linkages to emerging continu-
ous process technologies (e.g. in synthesis and work-up, fil-
tration, drying, secondary processing) to be effectively
exploited. The second current state mapping exercise exam-
ines network performance where, crystallisation workflow
outputs involving technology interventions inform 15 impact
variables, namely: inventory; lead-time to supply; lead-time to
market; scale-up (going into); volume flexibility (mix and vol-
ume); process control (including reliability and safety); quality
(purity); yield; IP protection and extension (including issue of
counterfeits); cost (process, packaging and transport); invest-
ment cost (incorporating financial impacts and return on invest-
ment); fiscal/tax; environmental impact; viability/adaptability
and asset utilisation. For these mapping exercises, the specific
implications of defined continuous technology developments
and readiness levels may be assessed using outputs from the
crystallisation workflow.
Finally, in this section, assessment of future state models
generally explores several potential future options prior to a
final decision, with alternative states based on emerging pro-
cess and production technologies that are still yet to be fully
developed. Critically, these alternative ‘states’ can be in-
formed/modelled using crystallisation workflow outputs.
Stages 2–7 of the crystallisation workflow can also support a
performance assessment of several potential technological
choices involving batch, continuous or hybrid routes, provid-
ing a benchmark – in terms of potential yield and purity, and
evaluating various scenarios, which may involve alternative
scale production footprints.
Future work in this area will focus on digital supply chains
and the integration of crystallisation-type workflows to enable
the rapid digital design of products and processes, to develop
design rules for manufacturing and supply chains, and con-
struct a library of functions to match (virtual) products to
their optimal supply chain design.
Fig. 16 Multi-dimensional scaling of RF prediction proximities.
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4.3. Formulation and drug product
Quality by Design (QbD) principles have been used to ad-
vance product and process quality in industry and have also
been adopted by the U.S. Food and Drug Administration
(FDA) and other regulatory agencies for the discovery, devel-
opment, and manufacture of drugs.110 Under a QbD ap-
proach, product and process performance characteristics are
scientifically designed to meet specific objectives, not merely
empirically derived from performance of test batches. The
formulation development of a drug product is based on drug
substance attributes and a target product profile (TPP), de-
tailing (amongst other product attributes) the desired dosage
form, dose range, release profile and shelf life. Ticehurst and
Marziano111 described that the internal structure (solid form
selection) and particle engineering of a drug substance are
interconnected to key API properties which in turn can affect
drug product attributes (Fig. 18). Both the TPP and the drug
substance attributes will influence the choice of excipients
for the drug product formulation, the processability of the
drug substance and the resulting formulation in downstream
processes (flowability, blending, compressibility), stability of
formulation/drug product as well as the product performance
(disintegration, dissolution, bioavailability).112
The systematic workflow approach for cooling
crystallisation design enables QbD and therefore should en-
able downstream processes in pharmaceutical drug develop-
ment to work with consistently high quality material and
avoid the costly variability often experienced in drug sub-
stances in batch processes.92 The resulting well characterised
continuous crystallisation process, based on data driven deci-
sions, will inform downstream product development pro-
cesses with much more detail regarding the drug substance
characteristics and particle engineering possibilities, which
in turn may allow the formulator to design processes that
can directly ‘dial a particle’ with the desired attributes. This
information may also allow for early identification of appro-
priate excipient selection and processing routes, focusing for-
mulation/drug product development activities in a much
more specific manner. Whilst significant progress has been
made in multi-scale modelling, further developments of the
underlying materials science and process physics will be re-
quired to realise this vision.
5. Conclusions and vision
Through this work, we have demonstrated how a systematic
workflow for the design of a seeded continuous cooling
crystallisation can be used to design and operate a robust
process to meet a specific target size by first intent. To
achieve this aim, the workflow comprises clearly defined
tasks that allow for data driven decisions. Lab automation
and design of experiment approaches have been shown to
minimise the resource requirements in both time and mate-
rials. To achieve this robustness, common crystallisation
Fig. 17 Workflow attributes informing supply chain design.
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issues such as agglomeration and fouling are identified at
an early stage by considering them during the solvent selec-
tion phase allowing them to be avoided without significant
rework. This first development and demonstration of the
workflow took 2 researchers 12 months with significant ad-
ditional ad hoc support from other researchers and re-
quired 5 kg of paracetamol. Subsequent demonstrations
with other APIs have taken a single researcher 3 months
with 500 g to complete (to be reported in follow-up
articles).
This workflow addresses a specific type of crystallisation
process with prescribed assumptions (solid state, impurity
profile, etc.). Therefore, the future direction for this research
is the development of workflows to address the limitations of
the current workflow (such as an unseeded version of the
cooling crystallisation and a workflow for the generation of
seed crystals), alternative crystallisations (anti-solvent, evapo-
rative, reactive, etc.) and to develop workflows for other unit
operations (filtration, washing, drying, formulation, etc.). In
some cases, these workflows will share common stages, e.g.
solvent screening and selection, to maximise development ef-
ficiency. An overarching workflow for selection of overall pro-
cess architecture is also a desirable goal. To enable a step
change in pharmaceutical manufacturing this higher-level
pathway could use product specifications and predictive tools
to be able to identify the required unit operations, select ap-
propriate workflows for process design and operate all unit
operations from fundamental molecular descriptors.
Nomenclature and abbreviations
Term Description
a Solubility parameter 1
b Solubility parameter 2
B Secondary nucleation rate (unit: # per min)
C Concentration (unit: g per kg solvent)
C(Tf) Solute concentration at final isolation temperature
(unit: g per kg solvent)
C(T0) Solute concentration at saturation temperature
(unit: g per kg solvent)
EA,g Activation energy (unit: J mol
−1)
g Order with respect to supersaturation
G Growth rate (unit: μm min−1)
kg Growth rate constant (unit: m s
−1)
Lp Product crystal size (unit: μm)
Ls Seed crystal size (unit: μm)
mseed Mass flow rate of seed crystals (unit: g min
−1)
msolvent Mass flow rate of solvent (unit: kg min
−1)
Mseed Mass ratio of seed or seed loading
N Particle count (unit: #)
RB Primary and secondary nucleation boundary ratio
S Supersaturation ratio
Primary nucleation supersaturation boundary
Secondary nucleation supersaturation boundary
T Temperature (unit: °C)
t0 Time vial is placed into crystalline (unit: min)
tn Time primary nucleation is expected (unit: min)
Fig. 18 The link between solid form selection (internal structure), particle engineering and key active pharmaceutical ingredient properties and
drug product attributes. Copyright (2015) Wiley. Used with permission from Ticehurst, M. D. and Marziano, I. (2015), Integration of active
pharmaceutical ingredient solid form selection and particle engineering into drug product design. J. Pharm. Pharmacol., 67, 782–802.
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Yt Mass theoretical yield (unit: %)
Greek letters
σ Relative supersaturation
τ Residence time (unit: min)
ΔTsd Temperature change required to double
solubility (unit: °C)
Abbreviation
API Active pharmaceutical ingredient
ATR Attenuated total reflectance
CM Continuous manufacturing
CPP Critical process parameter
CQA Critical quality attribute
CSD Crystal size distribution
DoE Design of experiments
DSC Differential scanning calorimetry
E.T. Elevated temperature
E2E End to end
FBRM Focused beam reflectance measurement
FTIR Fourier transform infrared spectroscopy
GC Gas chromatography
HPLC High performance liquid chromatography
ICH International conference on harmonisation
LC-MS Liquid chromatography-mass spectroscopy
MB-OBC Moving baffle oscillatory baffled crystalliser
MDS Multidimensional scale
MF-OBC Moving fluid oscillatory baffled crystalliser
MIR Mid infrared
MOC Material of construction
MOE Molecular operating environment
MSMPR Mixed suspension, mixed product removal
MSZW Metastable zone width
NIR Near infrared spectroscopy
NMR Nuclear magnetic resonance spectroscopy
PABA para-Aminobenzoic acid
PAT Process analytical technology
PBM Population balance model
PBT Pitched blade turbine
PFR Plug flow reactor
PLS Partial least squares
PSD Particle size distribution
QbD Quality by design
R.T. Room temperature
RF Random forest
RSWM Rotor stator wet mill
RTD Residence time distribution
SKU Stock keeping unit
TPP Target product profile
UPLC Ultra performance liquid chromatography
USP United States Pharmacopeia
UV-vis Ultraviolet-visible spectroscopy
XRD X-Ray diffraction
XRPD X-Ray powder diffraction
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